Skip to content
Paul M. Barr, M.D.

Paul M. Barr, M.D.

Cancer

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Locations

Wilmot Cancer Center

90 Crittenden Boulevard
Rochester, NY 14642

About Me

As the Director of the Clinical Trials Office for Wilmot Cancer Institute, I oversee our state-of-the-art clinical trials while also educating my patients about their disease so they are as informed as possible. This enables my patients to participate in the process of making the best treatment deci...
As the Director of the Clinical Trials Office for Wilmot Cancer Institute, I oversee our state-of-the-art clinical trials while also educating my patients about their disease so they are as informed as possible. This enables my patients to participate in the process of making the best treatment decisions.

Individual patients drew me into the field of hematology/oncology. I am driven by the desire to develop better, less toxic treatments for our lymphoma and leukemia patients. I also have an amazing team working with me that is focused on communicating with and educating our patients, helping them in every aspect of their lives.

If I were to recommend one thing to patients, it would be to ask about clinical trials. While a clinical trial may not be appropriate in every circumstance, all patients should learn about these important options.

Conditions I Treat

- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Chronic lymphocytic leukemia

Professional Background

Paul M. Barr, M.D. is an Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute.

Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at...
Paul M. Barr, M.D. is an Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute.

Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at Case Western Reserve University. He subsequently completed a hematology and oncology fellowship at Case Western and now holds subspecialty certification in Internal Medicine, Hematology and Oncology.

He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.

Certified Specialties

Hematology - American Board of Internal Medicine

Medical Oncology - American Board of Internal Medicine

Faculty Appointments

Professor - Department of Medicine, Hematology/Oncology (SMD)

Medical Director, Cancer Center Clinical Trials Office - Cancer Center

Professor - Cancer Center - Joint

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, University Hospitals Cleveland Medical Center. 2004 - 2007

Residency, Internal Medicine, University Hospitals Cleveland Medical Center. 2001 - 2003

Internship, Internal Medicine, University Hospitals Cleveland Medical Center. 2000 - 2001

Education

MD | Northeast Ohio Medical University. 2000

Awards

Lymphoma Research Foundation Clinical Investigator. 2012 - 2015

NIH Loan Repayment Program Award Recipient. 2011 - 2015

Wilmot Cancer Research Fellowship. 2011 - 2014

American Society of Hematology Clinical Research Training Institute. 2009

NIH/NCI K12 Paul Calabresi Scholar. 2008

John W. Harris, MD Hematology Scholar Award. 2006 - 2007

Chief Medical Resident. 2003 - 2004

Department of Zoology Honors Program. 1996

Phi Beta Kappa. 1996

Howard Hughes Summer Scholars Program. 1995

Miami MED Premedical Honorary. 1995

Research

Paul M. Barr, M.D. is an Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute.

Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at...
Paul M. Barr, M.D. is an Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute.

Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at Case Western Reserve University. He subsequently completed a hematology and oncology fellowship at Case Western and now holds subspecialty certification in Internal Medicine, Hematology and Oncology.

He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.

Clinical Trials

First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies

Lead Researcher: Paul M Barr

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult partici...

S1608:Testing two new targeted drug combinations against standard chemotherapy for early relapsing or refractory follicular lymphoma

Lead Researcher: Paul M Barr

This phase II trial studies how well obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular lymphoma that has come back (relapsed) or does not respond to treatment (re...

EA4151 ~ Phase III Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Lead Researcher: Paul M Barr

This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. M...

Publications

Journal Articles

Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.

Woyach JA, Perez Burbano GE, Ruppert AS, Miller CR, Heerema NA, Zhao W, Wall A, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Stephens DM, Brown JR, Lozanski G, Blachly JS, Nattam S, Larson RA, Erba HP, Litzow MR, Luger SM, Owen C, Kuzma C, Abramson JS, Little RF, Dinner SN, Stone RM, Uy GL, Stock W, Mandrekar SJ, Byrd JC

Blood.. 2024 January 12 Epub 01/12/2024.

Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.

Vose JM, Fu K, Wang L, Mansoor A, Stewart D, Cheng H, Smith L, Yuan J, Qureishi HN, Link BK, Cessna MH, Barr PM, Kahl BS, Mckinney MS, Khan N, Advani RH, Martin P, Goy AH, Phillips TJ, Mehta A, Kamdar M, Crump M, Pro B, Flowers CR, Jacobson CA, Smith SM, Stephens DM, Bachanova V, Jin Z, Wu S, Hernandez-Ilizaliturri F, Torka P, Anampa-Guzmán A, Kashef F, Li X, Sharma S, Greiner TC, Armitage JO, Lunning M, Weisenburger DD, Bociek RG, Iqbal J, Yu G, Bi C,

Journal of hematology & oncology.. 2023 December 1616 (1):122. Epub 12/16/2023.

T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features.

El Hussein S, Fang H, Jelloul FZ, Wang W, Loghavi S, Miranda RN, Friedberg JW, Burack WR, Evans AG, Xu J, Medeiros LJ

Archives of pathology & laboratory medicine.. 2023 December 7 Epub 12/07/2023.

ALK-rearranged CD30-positive poorly differentiated lung adenocarcinoma, mimicking anaplastic large-cell lymphoma.

George GV, Wallace DS, Wang Y, Carney J, Elsadawi M, Burack WR, Evans AG, Barr PM, Velez MJ, El Hussein S

Histopathology.. 2023 November 30 Epub 11/30/2023.

Expression analysis of pro-apoptotic and anti-apoptotic genes in relation to lactation performance in and crossbred cows.

Raj S R, D N D, Mondal S, Ashokan M, Thota LN, Karuthadurai T, J NKT, Ramesha KP

Animal biotechnology.. 2023 November 34 (4):1354-1361. Epub 01/22/2022.

Response-Adapted, Time-Limited Venetoclax, Umbralisib and Ublituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia.

Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani AS, Winter AM, Winter JN, Gordon LI, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM

Blood advances.. 2023 October 23 Epub 10/23/2023.

Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.

Rezazadeh A, Szabo A, Khurana A, Inwards DJ, Lunning MA, Bartlett NL, Caimi PF, Rodgers TD, Barr PM, Chowdhury SM, Epperla N, Mendries H, Hill BT, Oh TS, Karmali R, Chang JE, Goyal G, Parsons BM, Isaac KM, Portell CA, Monahan K, Siker M, King DM, Fenske TS

Haematologica.. 2023 October 19 Epub 10/19/2023.

First Double-Differential Measurement of Kinematic Imbalance in Neutrino Interactions with the MicroBooNE Detector.

Abratenko P, Alterkait O, Andrade Aldana D, Anthony J, Arellano L, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barr G, Barrow J, Basque V, Benevides Rodrigues O, Berkman S, Bhanderi A, Bhattacharya M, Bishai M, Blake A, Bogart B, Bolton T, Book JY, Camilleri L, Caratelli D, Caro Terrazas I, Cavanna F, Cerati G, Chen Y, Cohen EO, Conrad JM, Convery M, Cooper-Troendle L, Crespo-Anadón JI, Del Tutto M, Dennis SR, Detje P, Devitt A, Diurba R, Djurcic Z, Dorrill R, Duffy K, Dytman S, Eberly B, Ereditato A, Evans JJ, Fine R, Finnerud OG, Foreman W, Fleming BT, Foppiani N, Franco D, Furmanski AP, Garcia-Gamez D, Gardiner S, Ge G, Gollapinni S, Goodwin O, Gramellini E, Green P, Greenlee H, Gu W, Guenette R, Guzowski P, Hagaman L, Hen O, Hicks R, Hilgenberg C, Horton-Smith GA, Irwin B, Itay R, James C, Ji X, Jiang L, Jo JH, Johnson RA, Jwa YJ, Kalra D, Kamp N, Karagiorgi G, Ketchum W, Kirby M, Kobilarcik T, Kreslo I, Leibovitch MB, Lepetic I, Li JY, Li K, Li Y, Lin K, Littlejohn BR, Louis WC, Luo X, Mariani C, Marsden D, Marshall J, Martinez N, Martinez Caicedo DA, Mason K, Mastbaum A, McConkey N, Meddage V, Miller K, Mills J, Mogan A, Mohayai T, Mooney M, Moor AF, Moore CD, Mora Lepin L, Mousseau J, Mulleriababu S, Naples D, Navrer-Agasson A, Nayak N, Nebot-Guinot M, Nowak J, Oza N, Palamara O, Pallat N, Paolone V, Papadopoulou A, Papavassiliou V, Parkinson HB, Pate SF, Patel N, Pavlovic Z, Piasetzky E, Ponce-Pinto ID, Pophale I, Prince S, Qian X, Raaf JL, Radeka V, Rafique A, Reggiani-Guzzo M, Ren L, Rochester L, Rodriguez Rondon J, Rosenberg M, Ross-Lonergan M, Rudolf von Rohr C, Scanavini G, Schmitz DW, Schukraft A, Seligman W, Shaevitz MH, Sharankova R, Shi J, Snider EL, Soderberg M, Söldner-Rembold S, Spitz J, Stancari M, John JS, Strauss T, Sword-Fehlberg S, Szelc AM, Tang W, Taniuchi N, Terao K, Thorpe C, Torbunov D, Totani D, Toups M, Tsai YT, Tyler J, Uchida MA, Usher T, Viren B, Weber M, Wei H, White AJ, Williams Z, Wolbers S, Wongjirad T, Wospakrik M, Wresilo K, Wright N, Wu W, Yandel E, Yang T, Yates LE, Yu HW, Zeller GP, Zennamo J, Zhang C,

Physical review letters.. 2023 September 8131 (10):101802. Epub 1900 01 01.

Unpacking the CNS Manifestations of Epstein-Barr Virus: An Imaging Perspective.

Soni N, Ora M, Singh R, Mehta P, Agarwal A, Bathla G

AJNR. American journal of neuroradiology.. 2023 July 27 Epub 07/27/2023.

Dietary Patterns Are Not Associated With Disease Activity Among Patients With Inflammatory Conditions of the Pouch in a Prospective Cohort.

Barnes EL, Beniwal-Patel P, Deepak P, Raffals L, Kayal M, Dubinsky M, Chang S, Higgins PDR, Barr JI, Anderson C, Cross RK, Long MD, Herfarth HH

Crohn's & colitis 360.. 2023 July 5 (3):otad039. Epub 07/27/2023.

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.

Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Lisano JM, Wen R, Akyol A, Moskowitz AJ

Blood advances.. 2023 June 23 Epub 06/23/2023.

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.

Wallace DS, Rowland C, Hill BT, Baran AM, Casulo C, Reagan PM, Winter A, Karmali R, Winter JN, Gordon LI, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Ma S, Barr PM

Leukemia & lymphoma.. 2023 June 21 :1-4. Epub 06/21/2023.

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.

Allan JN, Flinn IW, Siddiqi T, Ghia P, Tam CS, Kipps TJ, Barr PM, Elinder Camburn A, Tedeschi A, Badoux XC, Jacobs R, Kuss BJ, Trentin L, Zhou C, Szoke A, Abbazio C, Wierda WG

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2023 June 7 :OF1-OF9. Epub 06/07/2023.

Current Concepts in Nodal Peripheral T-Cell Lymphomas.

Oishi N, Feldman AL

Surgical pathology clinics.. 2023 June 16 (2):267-285. Epub 04/03/2023.

Liver Fibrosis, Fat, and Iron Evaluation with MRI and Fibrosis and Fat Evaluation with US: A Practical Guide for Radiologists.

Guglielmo FF, Barr RG, Yokoo T, Ferraioli G, Lee JT, Dillman JR, Horowitz JM, Jhaveri KS, Miller FH, Modi RY, Mojtahed A, Ohliger MA, Pirasteh A, Reeder SB, Shanbhogue K, Silva AC, Smith EN, Surabhi VR, Taouli B, Welle CL, Yeh BM, Venkatesh SK

Radiographics : a review publication of the Radiological Society of North America, Inc.. 2023 June 43 (6):e220181. Epub 1900 01 01.

Quality of recovery following childbirth: a prospective, multicentre cohort study.

O'Carroll JE, Zucco L, Warwick E, Arbane G, Moonesinghe SR, El-Boghdadly K, Guo N, Carvalho B, Sultan P,

Anaesthesia.. 2023 May 24 Epub 05/24/2023.

Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population.

Thapa K, Strawderman M, Reagan PM, Barr PM, Zent CS, Friedberg JW, Faugh T, Casulo C

Clinical lymphoma, myeloma & leukemia.. 2023 May 23 Epub 05/23/2023.

Impact of Bronchiectasis on COPD Severity and Alpha-1 Antitrypsin Deficiency as a Risk Factor in Individuals with a Heavy Smoking History.

Izquierdo M, Marion CR, Genese F, Newell JD, O'Neal WK, Li X, Hawkins GA, Barjaktarevic I, Barr RG, Christenson S, Cooper CB, Couper D, Curtis J, Han MK, Hansel NN, Kanner RE, Martinez FJ, Paine R, Tejwani V, Woodruff PG, Zein JG, Hoffman EA, Peters SP, Meyers DA, Bleecker ER, Ortega VE,

Chronic obstructive pulmonary diseases.. 2023 May 16 Epub 05/16/2023.

Primary hepatic Epstein-Barr virus-positive diffuse large B-cell lymphoma associated with azathioprine immunosuppression: a case report.

Marell PS, Shi M, Wingo MT

Journal of medical case reports.. 2023 May 217 (1):175. Epub 05/02/2023.

Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis.

Weinstock JS, Gopakumar J, Burugula BB, Uddin MM, Jahn N, Belk JA, Bouzid H, Daniel B, Miao Z, Ly N, Mack TM, Luna SE, Prothro KP, Mitchell SR, Laurie CA, Broome JG, Taylor KD, Guo X, Sinner MF, von Falkenhausen AS, Kääb S, Shuldiner AR, O'Connell JR, Lewis JP, Boerwinkle E, Barnes KC, Chami N, Kenny EE, Loos RJF, Fornage M, Hou L, Lloyd-Jones DM, Redline S, Cade BE, Psaty BM, Bis JC, Brody JA, Silverman EK, Yun JH, Qiao D, Palmer ND, Freedman BI, Bowden DW, Cho MH, DeMeo DL, Vasan RS, Yanek LR, Becker LC, Kardia SLR, Peyser PA, He J, Rienstra M, Van der Harst P, Kaplan R, Heckbert SR, Smith NL, Wiggins KL, Arnett DK, Irvin MR, Tiwari H, Cutler MJ, Knight S, Muhlestein JB, Correa A, Raffield LM, Gao Y, de Andrade M, Rotter JI, Rich SS, Tracy RP, Konkle BA, Johnsen JM, Wheeler MM, Smith JG, Melander O, Nilsson PM, Custer BS, Duggirala R, Curran JE, Blangero J, McGarvey S, Williams LK, Xiao S, Yang M, Gu CC, Chen YI, Lee WJ, Marcus GM, Kane JP, Pullinger CR, Shoemaker MB, Darbar D, Roden DM, Albert C, Kooperberg C, Zhou Y, Manson JE, Desai P, Johnson AD, Mathias RA, , Blackwell TW, Abecasis GR, Smith AV, Kang HM, Satpathy AT, Natarajan P, Kitzman JO, Whitsel EA, Reiner AP, Bick AG, Jaiswal S

Nature.. 2023 April 12 Epub 04/12/2023.

Selective Bcl-2 inhibition promotes hematopoietic chimerism and allograft tolerance without myelosuppression in nonhuman primates.

Sasaki H, Hirose T, Oura T, Otsuka R, Rosales I, Ma D, Lassiter G, Karadagi A, Tomosugi T, Dehnadi A, Matsunami M, Raju Paul S, Reeves PM, Hanekamp I, Schwartz S, Colvin RB, Lee H, Spitzer TR, Cosimi AB, Cippà PE, Fehr T, Kawai T

Science translational medicine.. 2023 April 515 (690):eadd5318. Epub 04/05/2023.

Clinical course and features of persistent polyclonal B-cell lymphocytosis with BCL-6 amplification during pregnancy.

Galitzia A, Murru R, Caocci G, Barabino L, Azzena A, Licheri VM, Greco M, La Nasa G

European review for medical and pharmacological sciences.. 2023 April 27 (8):3514-3518. Epub 1900 01 01.

Reactivation of Parvovirus B19 Infection: An Uncommon Trigger of Macrophage Activation Syndrome in Adult-Onset Still's Disease.

Leelaviwat N, Armin S, Mekraksakit P, Nugent K

Cure?us.. 2023 April 15 (4):e37231. Epub 04/06/2023.

Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions.

Moore JE, Bloom PC, Chu CC, Bruno JE, Herne CA, Baran AM, Quataert SA, Mosmann TR, Taylor RP, Wallace DS, Elliott MR, Barr PM, Zent CS

Leukemia research.. 2023 March 29129 :107072. Epub 03/29/2023.

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.

Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, Emechebe N, Kamalakar R, Coombs CC, Leslie L, Barr PM, Brown JR, Eyre TA, Rampotas A, Schuh A, Lamanna N, Skarbnik A, Roeker LE, Bannerji R, Eichhorst B, Fleury I, Davids MS, Alhasani H, Jiang D, Hill BT, Schuster SJ, Brander DM, Pivneva I, Burne R, Guerin A, Mato AR

Clinical lymphoma, myeloma & leukemia.. 2023 March 24 Epub 03/24/2023.

Exosomes, microvesicles, and other extracellular vesicles-a Keystone Symposia report.

Cable J, Witwer KW, Coffey RJ, Milosavljevic A, von Lersner AK, Jimenez L, Pucci F, Barr MM, Dekker N, Barman B, Humphrys D, Williams J, de Palma M, Guo W, Bastos N, Hill AF, Levy E, Hantak MP, Crewe C, Aikawa E, Adamczyk AM, Zanotto TM, Ostrowski M, Arab T, Rabe DC, Sheikh A, da Silva DR, Jones JC, Okeoma C, Gaborski T, Zhang Q, Gololobova O

Annals of the New York Academy of Sciences.. 2023 March 18 Epub 03/18/2023.

Hemophagocytic Lymphohistiocytosis: an Under-recognized and Life-threatening Condition.

Poudyal BS, Poudel B, Tuladhar S, Rijal SS, Shrestha GS, Joshi U

Journal of Nepal Health Research Council.. 2023 March 1020 (3):794-796. Epub 03/10/2023.

A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.

Ryan CE, Brander DM, Barr PM, Tyekucheva S, Hackett LR, Collins MC, Fernandes SM, Ren Y, Zhou Y, McDonough MM, Walker HA, McEwan MR, Abramson JS, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR, Davids MS

Leukemia.. 2023 January 30 Epub 01/30/2023.

Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab for Initial Therapy of Chronic Lymphocytic Leukemia.

Wallace DS, Zent CS, Baran AM, Reagan PM, Casulo C, Rice G, Friedberg JW, Barr PM

Blood advances.. 2023 January 23 Epub 01/23/2023.

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ?5 Years in the RESONATE-2 Study.

Woyach JA, Barr PM, Kipps TJ, Barrientos JC, Ahn IE, Ghia P, Girardi V, Hsu E, Jermain M, Burger JA

Cancers.. 2023 January 1315 (2)Epub 01/13/2023.

Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.

Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Jermain M, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P

Future oncology.. 2023 January 9 Epub 01/09/2023.

First Constraints on Light Sterile Neutrino Oscillations from Combined Appearance and Disappearance Searches with the MicroBooNE Detector.

Abratenko P, Andrade Aldana D, Anthony J, Arellano L, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barr G, Barrow J, Basque V, Bathe-Peters L, Benevides Rodrigues O, Berkman S, Bhanderi A, Bhattacharya M, Bishai M, Blake A, Bogart B, Bolton T, Book JY, Camilleri L, Caratelli D, Caro Terrazas I, Cavanna F, Cerati G, Chen Y, Conrad JM, Convery M, Cooper-Troendle L, Crespo-Anadón JI, Del Tutto M, Dennis SR, Detje P, Devitt A, Diurba R, Dorrill R, Duffy K, Dytman S, Eberly B, Ereditato A, Evans JJ, Fine R, Finnerud OG, Foreman W, Fleming BT, Foppiani N, Franco D, Furmanski AP, Garcia-Gamez D, Gardiner S, Ge G, Gollapinni S, Goodwin O, Gramellini E, Green P, Greenlee H, Gu W, Guenette R, Guzowski P, Hagaman L, Hen O, Hicks R, Hilgenberg C, Horton-Smith GA, Irwin B, Itay R, James C, Ji X, Jiang L, Jo JH, Johnson RA, Jwa YJ, Kalra D, Kamp N, Karagiorgi G, Ketchum W, Kirby M, Kobilarcik T, Kreslo I, Leibovitch MB, Lepetic I, Li JY, Li K, Li Y, Lin K, Littlejohn BR, Louis WC, Luo X, Manivannan K, Mariani C, Marsden D, Marshall J, Martinez N, Martinez Caicedo DA, Mason K, Mastbaum A, McConkey N, Meddage V, Miller K, Mills J, Mogan A, Mohayai T, Mooney M, Moor AF, Moore CD, Mora Lepin L, Mousseau J, Mulleriababu S, Naples D, Navrer-Agasson A, Nayak N, Nebot-Guinot M, Nowak J, Nunes M, Oza N, Palamara O, Pallat N, Paolone V, Papadopoulou A, Papavassiliou V, Parkinson HB, Pate SF, Patel N, Pavlovic Z, Piasetzky E, Ponce-Pinto ID, Pophale I, Prince S, Qian X, Raaf JL, Radeka V, Reggiani-Guzzo M, Ren L, Rochester L, Rodriguez Rondon J, Rosenberg M, Ross-Lonergan M, Rudolf von Rohr C, Scanavini G, Schmitz DW, Schukraft A, Seligman W, Shaevitz MH, Sharankova R, Shi J, Smith A, Snider EL, Soderberg M, Söldner-Rembold S, Spitz J, Stancari M, St John J, Strauss T, Sword-Fehlberg S, Szelc AM, Tang W, Taniuchi N, Terao K, Thorpe C, Torbunov D, Totani D, Toups M, Tsai YT, Tyler J, Uchida MA, Usher T, Viren B, Weber M, Wei H, White AJ, Williams Z, Wolbers S, Wongjirad T, Wospakrik M, Wresilo K, Wright N, Wu W, Yandel E, Yang T, Yates LE, Yu HW, Zeller GP, Zennamo J, Zhang C,

Physical review letters.. 2023 January 6130 (1):011801. Epub 1900 01 01.

Immune dysregulation.

Long A, Kleiner A, Looney RJ

The Journal of allergy and clinical immunology.. 2023 January 151 (1):70-80. Epub 1900 01 01.

Canadian Spine Society: 23rd Annual Scientific Conference, Wednesday, March 1 - Saturday, March 4, Fairmont Le Château Frontenac, Québec, Que., Canada.

Birk M, Sidhu K, Filezio MR, Singh V, Ferri-de-Barros F, Chan V, Shumilak G, Nataraj A, Langston H, Yee NJ, Iorio C, Shkumat N, Rocos B, Ertl-Wagner B, Lebel D, Camp MW, Dimentberg E, Saran N, Laflamme M, Ouellet JA, Wenghofer J, Livock H, Beaton L, Tice A, Smit K, Graham R, Duarte MP, Roy-Beaudry M, Turgeon I, Joncas J, Mac-Thiong JM, Labelle H, Barchi S, Parent S, Gholamian T, Livock H, Tice A, Smit K, Yoon S, Zulfiqar A, Rocos B, Murphy A, Bath N, Moll S, Sorbara J, Lebel D, Camp MW, Nallet JA, Rocos B, Lebel DE, Zeller R, Dermott JA, Kim DJ, Anthony A, Zeller R, Lebel DE, Wang Z, Shen J, Kamel Y, Liu J, Shedid D, Al-Shakfa F, Yuh SJ, Boubez G, Rizkallah M, Rizkallah M, Shen J, Boubez G, Kamel Y, Liu J, Shedid D, Al-Shakfa F, Lavoie F, Yug SJ, Wang Z, Alavi F, Nielsen C, Rampersaud R, Lewis S, Cheung AM, Cadieux C, Fernandes R, Brzozowski P, Zdero R, Bailey C, Rasoulinejad P, Cherry A, Manoharan R, Xu M, Srikandarajah N, Iorio C, Raj A, Nielsen C, Rampersaud R, Lewis S, Beange K, Graham R, Livock H, Smit K, Manoharan R, Cherry A, Srikandarajah N, Raj A, Xu M, Iorio C, Nielsen CJ, Rampersaud YR, Lewis SJ, Nasrabadi AAM, Moammer G, Phee JM, Walker T, Urquhart JC, Glennie RA, Rampersaud YR, Fisher CG, Bailey CS, Herrington BJ, Fernandes RR, Urquhart JC, Rasoulinejad P, Siddiqi F, Bailey CS, Urquhart J, Fernandes RR, Glennie RA, Rampersaud YR, Fisher CG, Bailey CS, Yang MMH, Riva-Cambrin J, Cunningham J, Casha S, Cadieux CN, Urquhart J, Fernandes R, Glennie A, Fisher C, Rampersaud R, Xu M, Manoharan R, Cherry A, Raj A, Srikandarajah N, Iorio C, Nielsen C, Lewis S, Rampersaud R, Cherry A, Raj A, McIntosh G, Manoharan R, Murray JC, Nielsen C, Xu M, Srikandarajah N, Iorio C, Perruccio A, Canizares M, Rampersaud R, El-Mughayyar D, Bigney E, Richardson E, Manson N, Abraham E, Attabib N, Small C, Kolyvas G, LeRoux A, Outcomes CS, Investigators RN, Hebert J, Baisamy V, Rizkallah M, Shen J, Cresson T, Vazquez C, Wang Z, Boubez G, Lung T, Canizares M, Perruccio A, Rampersaud R, Crawford EJ, Ravinsky RA, Perruccio AV, Rampersaud YR, Coyte PC, Bond M, Street J, Fisher C, Charest-Morin R, Sutherland JM, Bartolozzi AR, Barzilai O, Chou D, Laufer I, Verlaan JJ, Sahgal A, Rhines LD, Scuibba DM, Lazary A, Weber MH, Schuster JM, Boriani S, Bettegowda C, Arnold PM, Clarke MJ, Fehlings MG, Reynolds JJ, Gokaslan ZL, Fisher CG, Dea N, Versteeg AL, Charest-Morin R, Laufer I, Teixeira W, Barzilai O, Gasbarrini A, Fehlings MG, Chou D, Johnson MG, Gokaslan ZL, Dea N, Verlaan JJ, Goldschlager T, Shin JH, O'Toole JE, Sciubba DM, Bettegowda C, Clarke MJ, Weber MH, Mesfin A, Kawahara N, Goodwin R, Disch A, Lazary A, Boriani S, Sahgal A, Rhines L, Fisher CG, Versteeg AL, Gal R, Reich L, Tsang A, Aludino A, Sahgal A, Verlaan JJ, Fisher CG, Verkooijen L, Rizkallah M, Wang Z, Yuh SJ, Shedid D, Shen J, Al-Shakfa F, Belguendouz C, AlKafi R, Boubez G, MacLean MA, Georgiopoulos M, Charest-Morin R, Germscheid N, Goodwin CR, Weber M, International AS, Rizkallah M, Boubez G, Zhang H, Al-Shakfa F, Brindamour P, Boule D, Shen J, Shedid D, Yuh SJ, Wang Z, Correale MR, Soever LJ, Rampersaud R, Malic CC, Dubreuil M, Duke K, Kingwell SP, Lin Z, MacLean MA, Julien LC, Patriquin G, LeBlanc J, Green R, Alant J, Barry S, Glennie RA, Oxney W, Christie SD, Sarraj M, Alqahtani A, Thornley P, Koziarz F, Bailey CS, Freire-Archer M, Bhanot K, Kachur E, Bhandari M, Oitment C, Malhotra AK, Balas M, Jaja BNR, Harrington EM, Hofereiter J, Jaffe RH, He Y, Byrne JP, Wilson JR, Witiw CD, Brittain KCM, Christie S, Pillai S, Dvorak MF, Evaniew N, Chen M, Waheed Z, Rotem-Kohavi N, Fallah N, Noonan VK, Fisher CG, Charest-Morin R, Dea N, Ailon T, Street J, Kwon BK, Sandarage RV, Galuta A, Ghinda D, Kwan JCS, TsaI EC, Hachem LD, Hong J, Velumian A, Mothe AJ, Tator CH, Fehlings MG, Shakil H, Jaja BNR, Zhang P, Jaffe R, Malhotra AK, Wilson JR, Witiw CD, Rotem-Kohavi N, Dvorak MF, Dea N, Evaniew N, Chen M, Waheed Z, Xu J, Fallah N, Noonan V, Kwon B, Dandurand C, Muijs S, Dvorak M, Schnake K, Cumhur , Ouml Ner , Greene R, Furlong B, Smith-Forrester J, Swab M, Christie SD, Hall A, Leck E, Marshall E, Christie S, Dvorak MF, Cumhur F, Ouml Ner , Vaccaro AR, Benneker LM, Rajasekaran S, El-Sharkawi M, Popescu EC, Tee JW, Paquet J, France JC, Allen R, Lavelle WF, Hirschfeld M, Pneumaticos S, Dandurand C, Cumhur , Ouml Ner , Muijs S, Schnake K, Dvorak M, Fernandes RR, Thornley P, Urquhart J, Kelly S, Alenezi N, Alahmari A, Siddiqi F, Singh S, Rasoulinejad P, Bailey C, Evaniew N, Burger LD, Dea N, Cadotte DW, McIntosh G, Jacobs B, St-Laurent-Lebeux L, Bourassa-Moreau É, Sarraj M, Majeed M, Guha D, Pahuta M, Laflamme M, McIntosh G, Dea N, Bak AB, Alvi MA, Moghaddamjou A, Fehlings MG, Silva YGMD, Goulet J, McIntosh G, Bedard S, Pimenta N, Blanchard J, Couture J, LaRue B, Investigators C, Adams T, Cunningham E, El-Mughayyar D, Bigney E, Vandewint A, Manson N, Abraham E, Small C, Attabib N, Richardson E, Hebert J, Bond M, Street J, Fisher C, Charest-Morin R, Sutherland JM, Hillier T, Bailey CS, Fisher C, Rampersaud R, Koto P, Glennie RA, Soroceanu A, Nicholls F, Thomas K, Evaniew N, Lewkonia P, Bouchard J, Jacobs B, Ben-Israel D, Crawford EJ, Fisher C, Dea N, Spackman E, Rampersaud R, Thomas KC, Srikandarajah N, Murray JC, Nielsen C, Manoharan R, Cherry A, Raj A, Xu M, Iorio C, Bailey C, Dea N, Fisher C, Hall H, Manson N, Thomas K, Canizares M, Rampersaud YR, Urquhart J, Fernandes RR, Glennie RA, Rampersaud YR, Fisher CG, Bailey C, Yang MMH, Far R, Sajobi T, Riva-Cambrin J, Casha S, Bond M, Street J, Fisher C, Charest-Morin R, Sutherland JM, Silva Y, Pimenta NG, LaRue B, Bedard S, Oviedo SC, Goulet J, Couture J, Blanchard J, McDonald J, Al-Jahdali F, Urquhart J, Alahmari A, Rampersaud R, Fisher C, Bailey C, Glennie A, Evaniew N, Coyle M, Rampersaud YR, Bailey CS, Jacobs WB, Cadotte DW, Thomas KC, Attabib N, Paquet J, Nataraj A, Christie SD, Weber MH, Phan P, Charest-Morin R, Fisher CG, Hall H, McIntosh G, Dea N, Malhotra AK, Davis AM, He Y, Harrington EM, Jaja BNR, Zhu MP, Shakil H, Dea N, Jacobs WB, Cadotte DW, Paquet J, Weber MH, Phan P, Christie SD, Nataraj A, Bailey CS, Johnson MG, Fisher CG, Manson N, Rampersaud YR, Thomas KC, Hall H, Fehlings MG, Ahn H, Ginsberg HJ, Witiw CD, Wilson JR, Althagafi A, McIntosh G, Charest-Morin R, Rizzuto MA, Ailon T, Dea N, Evaniew N, Jacobs BW, Paquet J, Rampersaud R, Hall H, Bailey CS, Weber M, Johnson MG, Nataraj A, Attabib N, Cadotte DW, Manson N, Stratton A, Christie SD, Thomas KC, Wilson JR, Fisher CG, Charest-Morin R, Bak AB, Alvi MA, Moghaddamjou A, Fehlings MG, Bak AB, Alvi MA, Moghaddamjou A, Fehlings MG, Soroceanu A, Nicholls F, Thomas K, Evaniew N, Salo P, Bouchard J, Jacobs B, Dandurand C, Laghaei PF, Ailon T, Charest-Morin R, Dea N, Dvorak M, Fisher C, Kwon BK, Paquette S, Street J, Soroceanu A, Nicholls F, Thomas K, Evaniew N, Bouchard J, Salo P, Jacobs B, Varshney VP, Sahjpaul R, Paquette S, Osborn J, Bak AB, Moghaddamjou A, Fehlings MG, Leck E, Marshall E, Christie S, Elkaim LM, Lasry OJ, Raj A, Murray JC, Cherry A, McIntosh G, Nielsen C, Srikandarajah N, Manoharan R, Iorio C, Xu M, Perruccio A, Canizares M, Rampersaud YR, Stratton A, Tierney S, Wai EK, Phan P, Kingwell S, Magnan MC, Soroceanu A, Nicholls F, Thomas K, Evaniew N, Salo P, Bouchard J, Jacobs B, Spanninga B, Hoelen TA, Johnson S, Arts JJC, Bailey CS, Urquhart JC, Glennie RA, Rampersaud YR, Fisher CG, Levett JJ, Elkaim LM, Alotaibi NM, Weber MH, Dea N, Abd-El-Barr MM, Cherry A, Yee A, Jaber N, Fehlings M, Cunningham E, Adams T, El-Mughayyar D, Bigney E, Vandewint A, Manson N, Abraham E, Small C, Attabib N, Richardson E, Hebert J, Werier J, Smit K, Villeneuve J, Sachs A, Abdelbary H, Al-Mosuli YK, Rakhra K, Phan P, Nagata K, Gum JL, Brown ME, Daniels CL, Carreon LY, Bonello JP, Koucheki R, Abbas A, Lex J, Nucci N, Whyne C, Larouche J, Ahn H, Finkelstein J, Lewis S, Toor J, Lee NJ, Orosz LD, Gum JL, Poulter GT, Jazini E, Haines CM, Good CR, Lehman RA, Crawford EJ, Ravinsky RA, Perruccio AV, Coyte PC, Rampersaud YR, Freire-Archer M, Sarraj M, AlShaalan F, Koziarz A, Thornley P, Alnemari H, Oitment C, Bharadwaj L, El-Mughayyar D, Bigney E, Manson N, Abraham E, Small C, Attabib N, Richardson E, Kearney J, Kundap U, Investigators C, Hebert J, Elkaim LM, Levett JJ, Niazi F, Bokhari R, Alotaibi NM, Lasry OJ, Bissonnette V, Yen D, Muddaluru VS, Gandhi P, Mastrolonardo A, Guha D, Pahuta MA, Christie SD, Vandertuin T, Ritcey G, Rainham D, Alhawsawi M, Mumtaz R, Abdelnour M, Qumquji F, Soroceanu A, Swamy G, Thomas K, Wai E, Phan P, Bhatt FR, Orosz LD, Yamout T, Good CR, Schuler TC, Nguyen T, Jazini E, Haines CM, Oppermann M, Gupta S, Ramjist J, Oppermann PS, Yang VXD, Levett JJ, Elkaim LM, Niazi F, Weber MH, Ioro-Morin C, Bonizzato M, Weil AG, Oppermann M, Ramjist J, Gupta S, Oppermann PS, Yang VXD, Jung Y, Muddalaru V, Gandhi P, Guha D, Koucheki R, Bonello JP, Abbas A, Lex JR, Nucci N, Whyne C, Yee A, Ahn H, Finkelstein J, Larouche J, Lewis S, Toor J, Dhawan A, Dhawan J, Sharma AN, Azzam DB, Cherry A, Fehlings MG, Orosz LD, Lee NJ, Yamout T, Gum JL, Lehman RA, Poulter GT, Haines CM, Jazini E, Good CR, Ridha BB, Persad A, Fourney D, Byers E, Gallagher M, Sugar J, Brown JL, Wang Z, Shen J, Boubez G, Al-Shakfa F, Yuh SJ, Shedid D, Rizkallah M, Singh M, Singh PK, Lawrence PL, Dell S, Goodluck-Tyndall R, Wade K, Morgan M, Bruce C, Silva YGMD, Pimenta N, LaRue B, Aldakhil S, Blanchard J, Couture J, Goulet J, Bednar DA, Raj R, Urquhart J, Bailey C, Christie SD, Greene R, Chaves JPG, Zarrabian M, Sigurdson L, Manoharan R, Cherry A, Iorio C, Srikandarajah N, Xu M, Raj A, Nielsen CJ, Rampersaud YR, Lewis SJ

Canadian journal of surgery. Journal canadien de chirurgie.. 2023 66 (4 Suppl 1):S1-S53. Epub 08/11/2023.

Measurements of neutrino oscillation parameters from the T2K experiment using protons on target.

Abe K, Akhlaq N, Akutsu R, Ali A, Alonso Monsalve S, Alt C, Andreopoulos C, Antonova M, Aoki S, Arihara T, Asada Y, Ashida Y, Atkin ET, Barbi M, Barker GJ, Barr G, Barrow D, Batkiewicz-Kwasniak M, Bench F, Berardi V, Berns L, Bhadra S, Blanchet A, Blondel A, Bolognesi S, Bonus T, Bordoni S, Boyd SB, Bravar A, Bronner C, Bron S, Bubak A, Buizza Avanzini M, Caballero JA, Calabria NF, Cao S, Carabadjac D, Carter AJ, Cartwright SL, Catanesi MG, Cervera A, Chakrani J, Cherdack D, Chong PS, Christodoulou G, Chvirova A, Cicerchia M, Coleman J, Collazuol G, Cook L, Cudd A, Dalmazzone C, Daret T, Davydov YI, De Roeck A, De Rosa G, Dealtry T, Delogu CC, Densham C, Dergacheva A, Di Lodovico F, Dolan S, Douqa D, Doyle TA, Drapier O, Dumarchez J, Dunne P, Dygnarowicz K, Eguchi A, Emery-Schrenk S, Erofeev G, Ershova A, Eurin G, Fedorova D, Fedotov S, Feltre M, Finch AJ, Fiorentini Aguirre GA, Fiorillo G, Fitton MD, Franco Patiño JM, Friend M, Fujii Y, Fukuda Y, Fusshoeller K, Giannessi L, Giganti C, Glagolev V, Gonin M, González Rosa J, Goodman EAG, Gorin A, Grassi M, Guigue M, Hadley DR, Haigh JT, Hamacher-Baumann P, Harris DA, Hartz M, Hasegawa T, Hassani S, Hastings NC, Hayato Y, Henaff D, Hiramoto A, Hogan M, Holeczek J, Holin A, Holvey T, Hong Van NT, Honjo T, Iacob F, Ichikawa AK, Ikeda M, Ishida T, Ishitsuka M, Israel HT, Iwamoto K, Izmaylov A, Izumi N, Jakkapu M, Jamieson B, Jenkins SJ, Jesús-Valls C, Jiang JJ, Jonsson P, Joshi S, Jung CK, Jurj PB, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Kasetti SP, Kataoka Y, Katayama Y, Katori T, Kawaue M, Kearns E, Khabibullin M, Khotjantsev A, Kikawa T, Kikutani H, King S, Kiseeva V, Kisiel J, Kobata T, Kobayashi H, Kobayashi T, Koch L, Kodama S, Konaka A, Kormos LL, Koshio Y, Kostin A, Koto T, Kowalik K, Kudenko Y, Kudo Y, Kuribayashi S, Kurjata R, Kutter T, Kuze M, La Commara M, Labarga L, Lachner K, Lagoda J, Lakshmi SM, Lamers James M, Lamoureux M, Langella A, Laporte JF, Last D, Latham N, Laveder M, Lavitola L, Lawe M, Lee Y, Lin C, Lin SK, Litchfield RP, Liu SL, Li W, Longhin A, Long KR, Lopez Moreno A, Ludovici L, Lu X, Lux T, Machado LN, Magaletti L, Mahn K, Malek M, Mandal M, Manly S, Marino AD, Marti-Magro L, Martin DGR, Martini M, Martin JF, Maruyama T, Matsubara T, Matveev V, Mauger C, Mavrokoridis K, Mazzucato E, McCauley N, McElwee J, McFarland KS, McGrew C, McKean J, Mefodiev A, Megias GD, Mehta P, Mellet L, Metelko C, Mezzetto M, Miller E, Minamino A, Mineev O, Mine S, Miura M, Molina Bueno L, Moriyama S, Moriyama S, Morrison P, Mueller TA, Munford D, Munteanu L, Nagai K, Nagai Y, Nakadaira T, Nakagiri K, Nakahata M, Nakajima Y, Nakamura A, Nakamura H, Nakamura K, Nakamura KD, Nakano Y, Nakayama S, Nakaya T, Nakayoshi K, Naseby CER, Ngoc TV, Nguyen VQ, Niewczas K, Nishimori S, Nishimura Y, Nishizaki K, Nosek T, Nova F, Novella P, Nugent JC, O'Keeffe HM, O'Sullivan L, Odagawa T, Ogawa T, Okada R, Okinaga W, Okumura K, Okusawa T, Ospina N, Owen RA, Oyama Y, Palladino V, Paolone V, Pari M, Parlone J, Parsa S, Pasternak J, Pavin M, Payne D, Penn GC, Pershey D, Pickering L, Pidcott C, Pintaudi G, Pistillo C, Popov B, Porwit K, Posiadala-Zezula M, Prabhu YS, Pupilli F, Quilain B, Radermacher T, Radicioni E, Radics B, Ramírez MA, Ratoff PN, Reh M, Riccio C, Rondio E, Roth S, Roy N, Rubbia A, Ruggeri AC, Ruggles CA, Rychter A, Sakashita K, Sánchez F, Santucci G, Schloesser CM, Scholberg K, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shaikhiev A, Shaker F, Shaykina A, Shiozawa M, Shorrock W, Shvartsman A, Skrobova N, Skwarczynski K, Smyczek D, Smy M, Sobczyk JT, Sobel H, Soler FJP, Sonoda Y, Speers AJ, Spina R, Suslov IA, Suvorov S, Suzuki A, Suzuki SY, Suzuki Y, Sztuc AA, Tada M, Tairafune S, Takayasu S, Takeda A, Takeuchi Y, Takifuji K, Tanaka HK, Tanihara Y, Tani M, Teklu A, Tereshchenko VV, Teshima N, Thamm N, Thompson LF, Toki W, Touramanis C, Towstego T, Tsui KM, Tsukamoto T, Tzanov M, Uchida Y, Vagins M, Vargas D, Varghese M, Vasseur G, Vilela C, Villa E, Vinning WGS, Virginet U, Vladisavljevic T, Wachala T, Walsh JG, Wang Y, Wan L, Wark D, Wascko MO, Weber A, Wendell R, Wilking MJ, Wilkinson C, Wilson JR, Wood K, Wret C, Xia J, Xu YH, Yamamoto K, Yamamoto T, Yanagisawa C, Yang G, Yano T, Yasutome K, Yershov N, Yevarouskaya U, Yokoyama M, Yoshimoto Y, Yoshimura N, Yu M, Zaki R, Zalewska A, Zalipska J, Zaremba K, Zarnecki G, Zhao X, Zhu T, Ziembicki M, Zimmerman ED, Zito M, Zsoldos S,

The European physical journal. C, Particles and fields.. 2023 83 (9):782. Epub 09/05/2023.

Dietary flavonoid carvacrol triggers the apoptosis of human breast cancer MCF-7 cells via the p53/Bax/Bcl-2 axis.

Moradipour A, Dariushnejad H, Ahmadizadeh C, Lashgarian HE

Medical oncology.. 2022 December 1040 (1):46. Epub 12/10/2022.

Synthesize of BiO/Gln-TSC nanoparticles and evaluation of their toxicity on prostate cancer cells and expression of CASP8, BAX, and Bcl-2 genes.

Moradi A, Abdihaji M, Kouchaksaraie SB, Alkinani TA, Mahmoudi A, Davoudi A, Dashtmiani W, Ghezeljeh SM, Aghajani S, Ghasemian R, Taramsari SM, Majlesi A, Niyaki ZM, Salehzadeh A

Scientific reports.. 2022 December 812 (1):21245. Epub 12/08/2022.

MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology.

Dutta AK, Alberge JB, Lightbody ED, Boehner CJ, Dunford A, Sklavenitis-Pistofidis R, Mouhieddine TH, Cowan AN, Su NK, Horowitz EM, Barr H, Hevenor L, Beckwith JB, Perry J, Cao A, Lin Z, Kuhr FK, Del Mastro RG, Nadeem O, Greipp PT, Stewart C, Auclair D, Getz G, Ghobrial IM

Cancer discovery.. 2022 December 7 Epub 12/07/2022.

Genetic diversity fuels gene discovery for tobacco and alcohol use.

Saunders GRB, Wang X, Chen F, Jang SK, Liu M, Wang C, Gao S, Jiang Y, Khunsriraksakul C, Otto JM, Addison C, Akiyama M, Albert CM, Aliev F, Alonso A, Arnett DK, Ashley-Koch AE, Ashrani AA, Barnes KC, Barr RG, Bartz TM, Becker DM, Bielak LF, Benjamin EJ, Bis JC, Bjornsdottir G, Blangero J, Bleecker ER, Boardman JD, Boerwinkle E, Boomsma DI, Boorgula MP, Bowden DW, Brody JA, Cade BE, Chasman DI, Chavan S, Chen YI, Chen Z, Cheng I, Cho MH, Choquet H, Cole JW, Cornelis MC, Cucca F, Curran JE, de Andrade M, Dick DM, Docherty AR, Duggirala R, Eaton CB, Ehringer MA, Esko T, Faul JD, Silva LF, Fiorillo E, Fornage M, Freedman BI, Gabrielsen ME, Garrett ME, Gharib SA, Gieger C, Gillespie N, Glahn DC, Gordon SD, Gu CC, Gu D, Gudbjartsson DF, Guo X, Haessler J, Hall ME, Haller T, Harris KM, He J, Herd P, Hewitt JK, Hickie I, Hidalgo B, Hokanson JE, Hopfer C, Hottenga J, Hou L, Huang H, Hung YJ, Hunter DJ, Hveem K, Hwang SJ, Hwu CM, Iacono W, Irvin MR, Jee YH, Johnson EO, Joo YY, Jorgenson E, Justice AE, Kamatani Y, Kaplan RC, Kaprio J, Kardia SLR, Keller MC, Kelly TN, Kooperberg C, Korhonen T, Kraft P, Krauter K, Kuusisto J, Laakso M, Lasky-Su J, Lee WJ, Lee JJ, Levy D, Li L, Li K, Li Y, Lin K, Lind PA, Liu C, Lloyd-Jones DM, Lutz SM, Ma J, Mägi R, Manichaikul A, Martin NG, Mathur R, Matoba N, McArdle PF, McGue M, McQueen MB, Medland SE, Metspalu A, Meyers DA, Millwood IY, Mitchell BD, Mohlke KL, Moll M, Montasser ME, Morrison AC, Mulas A, Nielsen JB, North KE, Oelsner EC, Okada Y, Orrù V, Palmer ND, Palviainen T, Pandit A, Park SL, Peters U, Peters A, Peyser PA, Polderman TJC, Rafaels N, Redline S, Reed RM, Reiner AP, Rice JP, Rich SS, Richmond NE, Roan C, Rotter JI, Rueschman MN, Runarsdottir V, Saccone NL, Schwartz DA, Shadyab AH, Shi J, Shringarpure SS, Sicinski K, Skogholt AH, Smith JA, Smith NL, Sotoodehnia N, Stallings MC, Stefansson H, Stefansson K, Stitzel JA, Sun X, Syed M, Tal-Singer R, Taylor AE, Taylor KD, Telen MJ, Thai KK, Tiwari H, Turman C, Tyrfingsson T, Wall TL, Walters RG, Weir DR, Weiss ST, White WB, Whitfield JB, Wiggins KL, Willemsen G, Willer CJ, Winsvold BS, Xu H, Yanek LR, Yin J, Young KL, Young KA, Yu B, Zhao W, Zhou W, Zöllner S, Zuccolo L, , , Batini C, Bergen AW, Bierut LJ, David SP, Gagliano Taliun SA, Hancock DB, Jiang B, Munafò MR, Thorgeirsson TE, Liu DJ, Vrieze S

Nature.. 2022 December 7 Epub 12/07/2022.

Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas.

Kirtane K, St John M, Fuentes-Bayne H, Patel SP, Mardiros A, Xu H, Ng EW, Go WY, Wong DJ, Sunwoo JB, Welch JS

Journal of clinical medicine.. 2022 December 711 (24)Epub 12/07/2022.

Hadh deficiency induced oligoasthenoteratozoospermia through the TNF-?/Bcl-2 pathway in male mice.

Zhu H, Wang H, Cheng Y, Liu D, Zhang A, Wen Z, Gao J

FASEB journal : official publication of the Federation of American Societies for Experimental Biology.. 2022 December 36 (12):e22661. Epub 1900 01 01.

Guidelines to Establish an Equitable Mobile Health Ecosystem.

Fortuna KL, Kadakia A, Cosco TD, Rotondi A, Nicholson J, Mois G, Myers AL, Hamilton J, Brewer LC, Collins-Pisano C, Barr P, Hudson MF, Joseph K, Mullaly C, Booth M, Lebby S, Walker R

Psychiatric services : a journal of the American Psychiatric Association.. 2022 November 15 :appips202200011. Epub 11/15/2022.

Adapting investigational drug services during a pandemic: Recommendations for future preparedness from the Hematology/Oncology Pharmacy Association Investigational Drug Services Special Interest Group.

Finnes HD, Child B, DeFrates S, Kinsman K, Thorne A, Lentz S, Lockhorst R, Murphy J, Urmanski A, Amin S, Barr H, Baviskar S, Beckman C, Chow N, Derba M, Erickson M, Hennes E, Heisey H, Lau R, Limvorasak S, Luckritz T, Mays T, Nzelibe CN, Romanowski T, Smith C, Tesoro D, Toeniskoetter K, Voytilla K

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.. 2022 October 6 Epub 10/06/2022.

CLL-418 Characteristics and Clinical Outcomes of Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Long-Term Ibrutinib Treatment in the RESONATE-2 Study.

Woyach JA, Barr PM, Kipps TJ, Barrientos JC, Ahn IE, Ghia P, Girardi V, Hsu E, Jermain M, Burger JA

Clinical lymphoma, myeloma & leukemia.. 2022 October 22 Suppl 2 :S278. Epub 1900 01 01.

CD138- Plasmablastic Lymphoma.

Choudhuri J, Pan Z, Yuan J, Chen M, Wu X, Zheng G, Zhao C, Yuan Y, Agarwal B, Liu J, Ma MY, Wang Y, Shi Y

Archives of pathology & laboratory medicine.. 2022 September 26 Epub 09/26/2022.

MOG and AQP4 antibodies among children with multiple sclerosis and controls.

Gaudioso CM, Mar S, Casper TC, Codden R, Nguyen A, Aaen G, Benson L, Chitnis T, Francisco C, Gorman MP, Goyal MS, Graves J, Greenberg BM, Hart J, Krupp L, Lotze T, Narula S, Pittock SJ, Rensel M, Rodriguez M, Rose J, Schreiner T, Tillema JM, Waldman A, Weinstock-Guttman B, Wheeler Y, Waubant E, Flanagan EP,

Annals of neurology.. 2022 September 11 Epub 09/11/2022.

Polymorphic variants of the CASP3, CASP9, BCL-2 and NKX3-1 genes as candidate markers for prostate cancer susceptibility and poor prognosis.

de Souza MR, de Souza MF, de Nóbrega M, Cilião HL, Dos Reis MB, Fuganti PE, Cólus IMS

Molecular biology reports.. 2022 September 49 (9):9079-9087. Epub 06/16/2022.

Microplastics and di (2-ethylhexyl) phthalate synergistically induce apoptosis in mouse pancreas through the GRP78/CHOP/Bcl-2 pathway activated by oxidative stress.

Wang Y, Zhang Y, Sun X, Shi X, Xu S

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.. 2022 September 167 :113315. Epub 07/19/2022.

Effective Tumor Debulking With Ibrutinib Before Initiation of Venetoclax: Results From the CAPTIVATE Minimal Residual Disease (MRD) and Fixed-Duration (FD) Cohorts.

Barr PM, Tedeschi A, Wierda WG, Allan JN, Ghia P, Vallisa D, Jacobs R, O'Brien S, Grigg AP, Walker P, Zhou C, Ninomoto J, Krigsfeld G, Tam CS

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2022 August 8 Epub 08/08/2022.

Search for Subsolar-Mass Binaries in the First Half of Advanced LIGO's and Advanced Virgo's Third Observing Run.

Abbott R, Abbott TD, Acernese F, Ackley K, Adams C, Adhikari N, Adhikari RX, Adya VB, Affeldt C, Agarwal D, Agathos M, Agatsuma K, Aggarwal N, Aguiar OD, Aiello L, Ain A, Ajith P, Albanesi S, Allocca A, Altin PA, Amato A, Anand C, Anand S, Ananyeva A, Anderson SB, Anderson WG, Andrade T, Andres N, Andri? T, Angelova SV, Ansoldi S, Antelis JM, Antier S, Appert S, Arai K, Araya MC, Areeda JS, Arène M, Arnaud N, Aronson SM, Arun KG, Asali Y, Ashton G, Assiduo M, Aston SM, Astone P, Aubin F, Austin C, Babak S, Badaracco F, Bader MKM, Badger C, Bae S, Baer AM, Bagnasco S, Bai Y, Baird J, Ball M, Ballardin G, Ballmer SW, Balsamo A, Baltus G, Banagiri S, Bankar D, Barayoga JC, Barbieri C, Barish BC, Barker D, Barneo P, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Barton MA, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley JC, Baylor AC, Bazzan M, Bécsy B, Bedakihale VM, Bejger M, Belahcene I, Benedetto V, Beniwal D, Bennett TF, Bentley JD, BenYaala M, Bergamin F, Berger BK, Bernuzzi S, Berry CPL, Bersanetti D, Bertolini A, Betzwieser J, Beveridge D, Bhandare R, Bhardwaj U, Bhattacharjee D, Bhaumik S, Bilenko IA, Billingsley G, Bini S, Birney R, Birnholtz O, Biscans S, Bischi M, Biscoveanu S, Bisht A, Biswas B, Bitossi M, Bizouard MA, Blackburn JK, Blair CD, Blair DG, Blair RM, Bobba F, Bode N, Boer M, Bogaert G, Boldrini M, Bonavena LD, Bondu F, Bonilla E, Bonnand R, Booker P, Boom BA, Bork R, Boschi V, Bose N, Bose S, Bossilkov V, Boudart V, Bouffanais Y, Bozzi A, Bradaschia C, Brady PR, Bramley A, Branch A, Branchesi M, Brau JE, Breschi M, Briant T, Briggs JH, Brillet A, Brinkmann M, Brockill P, Brooks AF, Brooks J, Brown DD, Brunett S, Bruno G, Bruntz R, Bryant J, Bulik T, Bulten HJ, Buonanno A, Buscicchio R, Buskulic D, Buy C, Byer RL, Cadonati L, Cagnoli G, Cahillane C, Bustillo JC, Callaghan JD, Callister TA, Calloni E, Cameron J, Camp JB, Canepa M, Canevarolo S, Cannavacciuolo M, Cannon KC, Cao H, Capote E, Carapella G, Carbognani F, Carlin JB, Carney MF, Carpinelli M, Carrillo G, Carullo G, Carver TL, Diaz JC, Casentini C, Castaldi G, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Ceasar M, Cella G, Cerdá-Durán P, Cesarini E, Chaibi W, Chakravarti K, Subrahmanya SC, Champion E, Chan CH, Chan C, Chan CL, Chan K, Chandra K, Chanial P, Chao S, Charlton P, Chase EA, Chassande-Mottin E, Chatterjee C, Chatterjee D, Chatterjee D, Chaturvedi M, Chaty S, Chatziioannou K, Chen HY, Chen J, Chen X, Chen Y, Chen Z, Cheng H, Cheong CK, Cheung HY, Chia HY, Chiadini F, Chiarini G, Chierici R, Chincarini A, Chiofalo ML, Chiummo A, Cho G, Cho HS, Choudhary RK, Choudhary S, Christensen N, Chu Q, Chua S, Chung KW, Ciani G, Ciecielag P, Cie?lar M, Cifaldi M, Ciobanu AA, Ciolfi R, Cipriano F, Cirone A, Clara F, Clark EN, Clark JA, Clarke L, Clearwater P, Clesse S, Cleva F, Coccia E, Codazzo E, Cohadon PF, Cohen DE, Cohen L, Colleoni M, Collette CG, Colombo A, Colpi M, Compton CM, Constancio M, Conti L, Cooper SJ, Corban P, Corbitt TR, Cordero-Carrión I, Corezzi S, Corley KR, Cornish N, Corre D, Corsi A, Cortese S, Costa CA, Cotesta R, Coughlin MW, Coulon JP, Countryman ST, Cousins B, Couvares P, Coward DM, Cowart MJ, Coyne DC, Coyne R, Creighton JDE, Creighton TD, Criswell AW, Croquette M, Crowder SG, Cudell JR, Cullen TJ, Cumming A, Cummings R, Cunningham L, Cuoco E, Cury?o M, Dabadie P, Canton TD, Dall'Osso S, Dálya G, Dana A, DaneshgaranBajastani LM, D'Angelo B, Danilishin S, D'Antonio S, Danzmann K, Darsow-Fromm C, Dasgupta A, Datrier LEH, Datta S, Dattilo V, Dave I, Davier M, Davies GS, Davis D, Davis MC, Daw EJ, Dean R, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Del Favero V, De Lillo F, De Lillo N, Del Pozzo W, DeMarchi LM, De Matteis F, D'Emilio V, Demos N, Dent T, Depasse A, De Pietri R, De Rosa R, De Rossi C, DeSalvo R, De Simone R, Dhurandhar S, Díaz MC, Diaz-Ortiz M, Didio NA, Dietrich T, Di Fiore L, Di Fronzo C, Di Giorgio C, Di Giovanni F, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Divakarla AK, Dmitriev A, Doctor Z, D'Onofrio L, Donovan F, Dooley KL, Doravari S, Dorrington I, Drago M, Driggers JC, Drori Y, Ducoin JG, Dupej P, Durante O, D'Urso D, Duverne PA, Dwyer SE, Eassa C, Easter PJ, Ebersold M, Eckhardt T, Eddolls G, Edelman B, Edo TB, Edy O, Effler A, Eichholz J, Eikenberry SS, Eisenmann M, Eisenstein RA, Ejlli A, Engelby E, Errico L, Essick RC, Estellés H, Estevez D, Etienne Z, Etzel T, Evans M, Evans TM, Ewing BE, Fafone V, Fair H, Fairhurst S, Farah AM, Farinon S, Farr B, Farr WM, Farrow NW, Fauchon-Jones EJ, Favaro G, Favata M, Fays M, Fazio M, Feicht J, Fejer MM, Fekecs B, Fenyvesi E, Ferguson DL, Fernandez-Galiana A, Ferrante I, Ferreira TA, Fidecaro F, Figura P, Fiori I, Fishbach M, Fisher RP, Fittipaldi R, Fiumara V, Flaminio R, Floden E, Fong H, Font JA, Fornal B, Forsyth PWF, Franke A, Frasca S, Frasconi F, Frederick C, Freed JP, Frei Z, Freise A, Frey R, Fritschel P, Frolov VV, Fronzé GG, Fulda P, Fyffe M, Gabbard HA, Gadre BU, Gair JR, Gais J, Galaudage S, Gamba R, Ganapathy D, Ganguly A, Gaonkar SG, Garaventa B, García-Núñez C, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gayathri V, Gemme G, Gennai A, George J, Gerberding O, Gergely L, Gewecke P, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Ghosh S, Giacomazzo B, Giacoppo L, Giaime JA, Giardina KD, Gibson DR, Gier C, Giesler M, Giri P, Gissi F, Glanzer J, Gleckl AE, Godwin P, Goetz E, Goetz R, Gohlke N, Goncharov B, González G, Gopakumar A, Gosselin M, Gouaty R, Gould DW, Grace B, Grado A, Granata M, Granata V, Grant A, Gras S, Grassia P, Gray C, Gray R, Greco G, Green AC, Green R, Gretarsson AM, Gretarsson EM, Griffith D, Griffiths W, Griggs HL, Grignani G, Grimaldi A, Grimm SJ, Grote H, Grunewald S, Gruning P, Guerra D, Guidi GM, Guimaraes AR, Guixé G, Gulati HK, Guo HK, Guo Y, Gupta A, Gupta A, Gupta P, Gustafson EK, Gustafson R, Guzman F, Haegel L, Halim O, Hall ED, Hamilton EZ, Hammond G, Haney M, Hanks J, Hanna C, Hannam MD, Hannuksela O, Hansen H, Hansen TJ, Hanson J, Harder T, Hardwick T, Haris K, Harms J, Harry GM, Harry IW, Hartwig D, Haskell B, Hasskew RK, Haster CJ, Haughian K, Hayes FJ, Healy J, Heidmann A, Heidt A, Heintze MC, Heinze J, Heinzel J, Heitmann H, Hellman F, Hello P, Helmling-Cornell AF, Hemming G, Hendry M, Heng IS, Hennes E, Hennig J, Hennig MH, Hernandez AG, Vivanco FH, Heurs M, Hild S, Hill P, Hines AS, Hochheim S, Hofman D, Hohmann JN, Holcomb DG, Holland NA, Hollows IJ, Holmes ZJ, Holt K, Holz DE, Hopkins P, Hough J, Hourihane S, Howell EJ, Hoy CG, Hoyland D, Hreibi A, Hsu Y, Huang Y, Hübner MT, Huddart AD, Hughey B, Hui V, Husa S, Huttner SH, Huxford R, Huynh-Dinh T, Idzkowski B, Iess A, Ingram C, Isi M, Isleif K, Iyer BR, JaberianHamedan V, Jacqmin T, Jadhav SJ, Jadhav SP, James AL, Jan AZ, Jani K, Janquart J, Janssens K, Janthalur NN, Jaranowski P, Jariwala D, Jaume R, Jenkins AC, Jenner K, Jeunon M, Jia W, Johns GR, Jones AW, Jones DI, Jones JD, Jones P, Jones R, Jonker RJG, Ju L, Junker J, Juste V, Kalaghatgi CV, Kalogera V, Kamai B, Kandhasamy S, Kang G, Kanner JB, Kao Y, Kapadia SJ, Kapasi DP, Karat S, Karathanasis C, Karki S, Kashyap R, Kasprzack M, Kastaun W, Katsanevas S, Katsavounidis E, Katzman W, Kaur T, Kawabe K, Kéfélian F, Keitel D, Key JS, Khadka S, Khalili FY, Khan S, Khazanov EA, Khetan N, Khursheed M, Kijbunchoo N, Kim C, Kim JC, Kim K, Kim WS, Kim YM, Kimball C, Kinley-Hanlon M, Kirchhoff R, Kissel JS, Kleybolte L, Klimenko S, Knee AM, Knowles TD, Knyazev E, Koch P, Koekoek G, Koley S, Kolitsidou P, Kolstein M, Komori K, Kondrashov V, Kontos A, Koper N, Korobko M, Kovalam M, Kozak DB, Kringel V, Krishnendu NV, Królak A, Kuehn G, Kuei F, Kuijer P, Kumar A, Kumar P, Kumar R, Kumar R, Kuns K, Kuwahara S, Lagabbe P, Laghi D, Lalande E, Lam TL, Lamberts A, Landry M, Lane BB, Lang RN, Lange J, Lantz B, La Rosa I, Lartaux-Vollard A, Lasky PD, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lecoeuche YK, Lee HM, Lee HW, Lee J, Lee K, Lehmann J, Lemaître A, Leroy N, Letendre N, Levesque C, Levin Y, Leviton JN, Leyde K, Li AKY, Li B, Li J, Li TGF, Li X, Linde F, Linker SD, Linley JN, Littenberg TB, Liu J, Liu K, Liu X, Llamas F, Llorens-Monteagudo M, Lo RKL, Lockwood A, London LT, Longo A, Lopez D, Portilla ML, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lott TP, Lough JD, Lousto CO, Lovelace G, Lucaccioni JF, Lück H, Lumaca D, Lundgren AP, Lynam JE, Macas R, MacInnis M, Macleod DM, MacMillan IAO, Macquet A, Hernandez IM, Magazzù C, Magee RM, Maggiore R, Magnozzi M, Mahesh S, Majorana E, Makarem C, Maksimovic I, Maliakal S, Malik A, Man N, Mandic V, Mangano V, Mango JL, Mansell GL, Manske M, Mantovani M, Mapelli M, Marchesoni F, Marion F, Mark Z, Márka S, Márka Z, Markakis C, Markosyan AS, Markowitz A, Maros E, Marquina A, Marsat S, Martelli F, Martin IW, Martin RM, Martinez M, Martinez VA, Martinez V, Martinovic K, Martynov DV, Marx EJ, Masalehdan H, Mason K, Massera E, Masserot A, Massinger TJ, Masso-Reid M, Mastrogiovanni S, Matas A, Mateu-Lucena M, Matichard F, Matiushechkina M, Mavalvala N, McCann JJ, McCarthy R, McClelland DE, McClincy PK, McCormick S, McCuller L, McGhee GI, McGuire SC, McIsaac C, McIver J, McRae T, McWilliams ST, Meacher D, Mehmet M, Mehta AK, Meijer Q, Melatos A, Melchor DA, Mendell G, Menendez-Vazquez A, Menoni CS, Mercer RA, Mereni L, Merfeld K, Merilh EL, Merritt JD, Merzougui M, Meshkov S, Messenger C, Messick C, Meyers PM, Meylahn F, Mhaske A, Miani A, Miao H, Michaloliakos I, Michel C, Middleton H, Milano L, Miller A, Miller AL, Miller B, Millhouse M, Mills JC, Milotti E, Minazzoli O, Minenkov Y, Mir LM, Miravet-Tenés M, Mishra C, Mishra T, Mistry T, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Mo G, Moguel E, Mogushi K, Mohapatra SRP, Mohite SR, Molina I, Molina-Ruiz M, Mondin M, Montani M, Moore CJ, Moraru D, Morawski F, More A, Moreno C, Moreno G, Morisaki S, Mours B, Mow-Lowry CM, Mozzon S, Muciaccia F, Mukherjee A, Mukherjee D, Mukherjee S, Mukherjee S, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz EA, Murray PG, Musenich R, Muusse S, Nadji SL, Nagar A, Napolano V, Nardecchia I, Naticchioni L, Nayak B, Nayak RK, Neil BF, Neilson J, Nelemans G, Nelson TJN, Nery M, Neubauer P, Neunzert A, Ng KY, Ng SWS, Nguyen C, Nguyen P, Nguyen T, Nichols SA, Nissanke S, Nitoglia E, Nocera F, Norman M, North C, Nuttall LK, Oberling J, O'Brien BD, O'Dell J, Oelker E, Oganesyan G, Oh JJ, Oh SH, Ohme F, Ohta H, Okada MA, Olivetto C, Oram R, O'Reilly B, Ormiston RG, Ormsby ND, Ortega LF, O'Shaughnessy R, O'Shea E, Ossokine S, Osthelder C, Ottaway DJ, Overmier H, Pace AE, Pagano G, Page MA, Pagliaroli G, Pai A, Pai SA, Palamos JR, Palashov O, Palomba C, Pan H, Panda PK, Pang PTH, Pankow C, Pannarale F, Pant BC, Panther FH, Paoletti F, Paoli A, Paolone A, Park H, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patel M, Pathak M, Patricelli B, Patron AS, Paul S, Payne E, Pedraza M, Pegoraro M, Pele A, Penn S, Perego A, Pereira A, Pereira T, Perez CJ, Périgois C, Perkins CC, Perreca A, Perriès S, Petermann J, Petterson D, Pfeiffer HP, Pham KA, Phukon KS, Piccinni OJ, Pichot M, Piendibene M, Piergiovanni F, Pierini L, Pierro V, Pillant G, Pillas M, Pilo F, Pinard L, Pinto IM, Pinto M, Piotrzkowski K, Pirello M, Pitkin MD, Placidi E, Planas L, Plastino W, Pluchar C, Poggiani R, Polini E, Pong DYT, Ponrathnam S, Popolizio P, Porter EK, Poulton R, Powell J, Pracchia M, Pradier T, Prajapati AK, Prasai K, Prasanna R, Pratten G, Principe M, Prodi GA, Prokhorov L, Prosposito P, Prudenzi L, Puecher A, Punturo M, Puosi F, Puppo P, Pürrer M, Qi H, Quetschke V, Quitzow-James R, Raab FJ, Raaijmakers G, Radkins H, Radulesco N, Raffai P, Rail SX, Raja S, Rajan C, Ramirez KE, Ramirez TD, Ramos-Buades A, Rana J, Rapagnani P, Rapol UD, Ray A, Raymond V, Raza N, Razzano M, Read J, Rees LA, Regimbau T, Rei L, Reid S, Reid SW, Reitze DH, Relton P, Renzini A, Rettegno P, Rezac M, Ricci F, Richards D, Richardson JW, Richardson L, Riemenschneider G, Riles K, Rinaldi S, Rink K, Rizzo M, Robertson NA, Robie R, Robinet F, Rocchi A, Rodriguez S, Rolland L, Rollins JG, Romanelli M, Romano R, Romel CL, Romero-Rodríguez A, Romero-Shaw IM, Romie JH, Ronchini S, Rosa L, Rose CA, Rosi?ska D, Ross MP, Rowan S, Rowlinson SJ, Roy S, Roy S, Roy S, Rozza D, Ruggi P, Ryan K, Sachdev S, Sadecki T, Sadiq J, Sakellariadou M, Salafia OS, Salconi L, Saleem M, Salemi F, Samajdar A, Sanchez EJ, Sanchez JH, Sanchez LE, Sanchis-Gual N, Sanders JR, Sanuy A, Saravanan TR, Sarin N, Sassolas B, Satari H, Sathyaprakash BS, Sauter O, Savage RL, Sawant D, Sawant HL, Sayah S, Schaetzl D, Scheel M, Scheuer J, Schiworski M, Schmidt P, Schmidt S, Schnabel R, Schneewind M, Schofield RMS, Schönbeck A, Schulte BW, Schutz BF, Schwartz E, Scott J, Scott SM, Seglar-Arroyo M, Sellers D, Sengupta AS, Sentenac D, Seo EG, Sequino V, Sergeev A, Setyawati Y, Shaffer T, Shahriar MS, Shams B, Sharma A, Sharma P, Shawhan P, Shcheblanov NS, Shikauchi M, Shoemaker DH, Shoemaker DM, ShyamSundar S, Sieniawska M, Sigg D, Singer LP, Singh D, Singh N, Singha A, Sintes AM, Sipala V, Skliris V, Slagmolen BJJ, Slaven-Blair TJ, Smetana J, Smith JR, Smith RJE, Soldateschi J, Somala SN, Son EJ, Soni K, Soni S, Sordini V, Sorrentino F, Sorrentino N, Soulard R, Souradeep T, Sowell E, Spagnuolo V, Spencer AP, Spera M, Srinivasan R, Srivastava AK, Srivastava V, Staats K, Stachie C, Steer DA, Steinlechner J, Steinlechner S, Stevenson S, Stops DJ, Stover M, Strain KA, Strang LC, Stratta G, Strunk A, Sturani R, Stuver AL, Sudhagar S, Sudhir V, Suh HG, Summerscales TZ, Sun H, Sun L, Sunil S, Sur A, Suresh J, Sutton PJ, Swinkels BL, Szczepa?czyk MJ, Szewczyk P, Tacca M, Tait SC, Talbot CJ, Talbot C, Tanasijczuk AJ, Tanner DB, Tao D, Tao L, Martín ENTS, Taranto C, Tasson JD, Tenorio R, Terhune JE, Terkowski L, Thirugnanasambandam MP, Thomas M, Thomas P, Thompson JE, Thondapu SR, Thorne KA, Thrane E, Tiwari S, Tiwari S, Tiwari V, Toivonen AM, Toland K, Tolley AE, Tonelli M, Torres-Forné A, Torrie CI, E Melo IT, Töyrä D, Trapananti A, Travasso F, Traylor G, Trevor M, Tringali MC, Tripathee A, Troiano L, Trovato A, Trozzo L, Trudeau RJ, Tsai DS, Tsai D, Tsang KW, Tse M, Tso R, Tsukada L, Tsuna D, Tsutsui T, Turbang K, Turconi M, Ubhi AS, Udall RP, Ueno K, Unnikrishnan CS, Urban AL, Utina A, Vahlbruch H, Vajente G, Vajpeyi A, Valdes G, Valentini M, Valsan V, van Bakel N, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, Vander-Hyde DC, van der Schaaf L, van Heijningen JV, Vanosky J, van Remortel N, Vardaro M, Vargas AF, Varma V, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venneberg J, Venugopalan G, Verkindt D, Verma P, Verma Y, Veske D, Vetrano F, Viceré A, Vidyant S, Viets AD, Vijaykumar A, Villa-Ortega V, Vinet JY, Virtuoso A, Vitale S, Vo T, Vocca H, von Reis ERG, von Wrangel JSA, Vorvick C, Vyatchanin SP, Wade LE, Wade M, Wagner KJ, Walet RC, Walker M, Wallace GS, Wallace L, Walsh S, Wang JZ, Wang WH, Ward RL, Warner J, Was M, Washington NY, Watchi J, Weaver B, Webster SA, Weinert M, Weinstein AJ, Weiss R, Weller CM, Wellmann F, Wen L, Weßels P, Wette K, Whelan JT, White DD, Whiting BF, Whittle C, Wilken D, Williams D, Williams MJ, Williamson AR, Willis JL, Willke B, Wilson DJ, Winkler W, Wipf CC, Wlodarczyk T, Woan G, Woehler J, Wofford JK, Wong ICF, Wu DS, Wysocki DM, Xiao L, Yamamoto H, Yang FW, Yang L, Yang Y, Yang Z, Yap MJ, Yeeles DW, Yelikar AB, Ying M, Yoo J, Yu H, Yu H, Zadro?ny A, Zanolin M, Zelenova T, Zendri JP, Zevin M, Zhang J, Zhang L, Zhang T, Zhang Y, Zhao C, Zhao G, Zhao Y, Zhou R, Zhou Z, Zhu XJ, Zimmerman AB, Zucker ME, Zweizig J, Jeong D, Shandera S,

Physical review letters.. 2022 August 5129 (6):061104. Epub 1900 01 01.

Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association.

Oishi N, Satou A, Miyaoka M, Kawashima I, Segawa T, Miyake K, Mochizuki K, Kirito K, Feldman A, Nakamura N, Kondo T

Blood advances.. 2022 July 26 Epub 07/26/2022.

Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.

Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, Rosenbaum C, Ujjani C, Barr PM, Unger JM, Cheson BD, Bartlett NL, Kahl B, Friedberg JW, Mandrekar SJ, Leonard JP

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2022 July 5 :JCO2102301. Epub 07/05/2022.

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.

Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, Barr PM, Allan JN, Šimkovi? M, Leslie LA, Rhodes J, Chong EA, Kamdar M, Skarbnik AP, Lansigan F, McCall BJ, Saja K, Dyer MJS, Walter HS, Lefebure M, Thadani-Mulero M, Boyer M, Biondo JML, Sail K, Manzoor BS, Furman RR, Bantilan KS, Goy A, Feldman T, Labella D, Schuster SJ, Park JH, Palomba ML, Zelenetz AD, Eyre TA, Kater AP, Seymour JF, Mato AR

Blood advances.. 2022 June 23 Epub 06/23/2022.

Search for an Excess of Electron Neutrino Interactions in MicroBooNE Using Multiple Final-State Topologies.

Abratenko P, An R, Anthony J, Arellano L, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barnes C, Barr G, Basque V, Bathe-Peters L, Benevides Rodrigues O, Berkman S, Bhanderi A, Bhat A, Bishai M, Blake A, Bolton T, Book JY, Camilleri L, Caratelli D, Caro Terrazas I, Cavanna F, Cerati G, Chen Y, Cianci D, Collin GH, Conrad JM, Convery M, Cooper-Troendle L, Crespo-Anadón JI, Del Tutto M, Dennis SR, Detje P, Devitt A, Diurba R, Dorrill R, Duffy K, Dytman S, Eberly B, Ereditato A, Escudero Sanchez L, Evans JJ, Fine R, Fiorentini Aguirre GA, Fitzpatrick RS, Fleming BT, Foppiani N, Franco D, Furmanski AP, Garcia-Gamez D, Gardiner S, Ge G, Genty V, Gollapinni S, Goodwin O, Gramellini E, Green P, Greenlee H, Gu W, Guenette R, Guzowski P, Hagaman L, Hen O, Hilgenberg C, Horton-Smith GA, Hourlier A, Itay R, James C, Ji X, Jiang L, Jo JH, Johnson RA, Jwa YJ, Kaleko D, Kalra D, Kamp N, Kaneshige N, Karagiorgi G, Ketchum W, Kirby M, Kobilarcik T, Kreslo I, LaZur R, Lepetic I, Li K, Li Y, Lin K, Lister A, Littlejohn BR, Louis WC, Luo X, Manivannan K, Mariani C, Marsden D, Marshall J, Martinez Caicedo DA, Mason K, Mastbaum A, McConkey N, Meddage V, Mettler T, Miller K, Mills J, Mistry K, Mogan A, Mohayai T, Moon J, Mooney M, Moor AF, Moore CD, Mora Lepin L, Mousseau J, Murphy M, Naples D, Navrer-Agasson A, Nebot-Guinot M, Neely RK, Newmark DA, Nowak J, Nunes M, Palamara O, Paolone V, Papadopoulou A, Papavassiliou V, Pate SF, Patel N, Paudel A, Pavlovic Z, Piasetzky E, Ponce-Pinto ID, Prince S, Qian X, Raaf JL, Radeka V, Rafique A, Reggiani-Guzzo M, Ren L, Rice LCJ, Rochester L, Rodriguez Rondon J, Rosenberg M, Ross-Lonergan M, Russell B, Scanavini G, Schmitz DW, Schukraft A, Seligman W, Shaevitz MH, Sharankova R, Shi J, Sinclair J, Smith A, Snider EL, Soderberg M, Söldner-Rembold S, Soleti SR, Spentzouris P, Spitz J, Stancari M, John JS, Strauss T, Sutton K, Sword-Fehlberg S, Szelc AM, Tang W, Terao K, Thomson M, Thorpe C, Totani D, Toups M, Tsai YT, Uchida MA, Usher T, Van De Pontseele W, Viren B, Weber M, Wei H, Williams Z, Wolbers S, Wongjirad T, Wospakrik M, Wresilo K, Wright N, Wu W, Yandel E, Yang T, Yarbrough G, Yates LE, Yu HW, Zeller GP, Zennamo J, Zhang C,

Physical review letters.. 2022 June 17128 (24):241801. Epub 1900 01 01.

eQTL set-based association analysis identifies novel susceptibility loci for Barrett's esophagus and esophageal adenocarcinoma.

Wang X, Gharahkhani P, Levine DM, Fitzgerald RC, Gockel I, Corley DA, Risch HA, Bernstein L, Chow WH, Onstad L, Shaheen NJ, Lagergren J, Hardie LJ, Wu AH, Pharoah PDP, Liu G, Anderson LA, Iyer PG, Gammon MD, Caldas C, Ye W, Barr H, Moayyedi P, Harrison R, Watson RP, Attwood S, Chegwidden L, Love SB, MacDonald D, deCaestecker J, Prenen H, Ott K, Moebus S, Venerito M, Lang H, Mayershofer R, Knapp M, Veits L, Gerges C, Weissmüller J, Reeh M, Nöthen MM, Izbicki JR, Manner H, Neuhaus H, Rösch T, Böhmer AC, Hölscher AH, Anders M, Pech O, Schumacher B, Schmidt C, Schmidt T, Noder T, Lorenz D, Vieth M, May A, Hess T, Kreuser N, Becker J, Ell C, Tomlinson I, Palles C, Jankowski JA, Whiteman DC, MacGregor S, Schumacher J, Vaughan TL, Buas MF, Dai JY

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 2022 June 16 Epub 06/16/2022.

Characterization of primary cutaneous T-cell lymphoma following solid organ transplantation.

Shimshak S, Dai C, Comfere N, Sokumbi O

International journal of dermatology.. 2022 June 10 Epub 06/10/2022.

Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics.

Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.. 2022 May 13 Epub 05/13/2022.

Development of the Endoscopic Pouch Score for Assessment of Inflammatory Conditions of the Pouch.

Barnes EL, Long MD, Raffals L, Isaacs K, Stidham RW, Herfarth HH,

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.. 2022 May 11 Epub 05/11/2022.

The immunogenetics of viral antigen response is associated with subtype-specific glioma risk and survival.

Guerra G, Kachuri L, Wendt G, Hansen HM, Mack SJ, Molinaro AM, Rice T, Bracci P, Wiencke JK, Kasahara N, Eckel-Passow JE, Jenkins RB, Wrensch M, Francis SS

American journal of human genetics.. 2022 May 6 Epub 05/06/2022.

A Case of Painless Subacute Thyroiditis Presenting as Fever of Unknown Origin.

Neupane B, Karki S, Tirthani E, Jadhav N, Gupta N

Cure?us.. 2022 May 14 (5):e24949. Epub 05/12/2022.

Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial.

Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos JC, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba HP, Stone RM, Litzow MR, Tallman MS, Kay NE

Blood.. 2022 April 15 Epub 04/15/2022.

First Measurement of Energy-Dependent Inclusive Muon Neutrino Charged-Current Cross Sections on Argon with the MicroBooNE Detector.

Abratenko P, An R, Anthony J, Arellano L, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barnes C, Barr G, Basque V, Bathe-Peters L, Benevides Rodrigues O, Berkman S, Bhanderi A, Bhat A, Bishai M, Blake A, Bolton T, Book JY, Camilleri L, Caratelli D, Caro Terrazas I, Cavanna F, Cerati G, Chen Y, Cianci D, Conrad JM, Convery M, Cooper-Troendle L, Crespo-Anadón JI, Del Tutto M, Dennis SR, Detje P, Devitt A, Diurba R, Dorrill R, Duffy K, Dytman S, Eberly B, Ereditato A, Evans JJ, Fine R, Fiorentini Aguirre GA, Fitzpatrick RS, Fleming BT, Foppiani N, Franco D, Furmanski AP, Garcia-Gamez D, Gardiner S, Ge G, Gollapinni S, Goodwin O, Gramellini E, Green P, Greenlee H, Gu W, Guenette R, Guzowski P, Hagaman L, Hen O, Hilgenberg C, Horton-Smith GA, Hourlier A, Itay R, James C, Ji X, Jiang L, Jo JH, Johnson RA, Jwa YJ, Kalra D, Kamp N, Kaneshige N, Karagiorgi G, Ketchum W, Kirby M, Kobilarcik T, Kreslo I, Lepetic I, Li K, Li Y, Lin K, Littlejohn BR, Louis WC, Luo X, Manivannan K, Mariani C, Marsden D, Marshall J, Martinez Caicedo DA, Mason K, Mastbaum A, McConkey N, Meddage V, Mettler T, Miller K, Mills J, Mistry K, Mogan A, Mohayai T, Moon J, Mooney M, Moor AF, Moore CD, Mora Lepin L, Mousseau J, Murphy M, Naples D, Navrer-Agasson A, Nebot-Guinot M, Neely RK, Newmark DA, Nowak J, Nunes M, Palamara O, Paolone V, Papadopoulou A, Papavassiliou V, Pate SF, Patel N, Paudel A, Pavlovic Z, Piasetzky E, Ponce-Pinto ID, Prince S, Qian X, Raaf JL, Radeka V, Rafique A, Reggiani-Guzzo M, Ren L, Rice LCJ, Rochester L, Rodriguez Rondon J, Rosenberg M, Ross-Lonergan M, Scanavini G, Schmitz DW, Schukraft A, Seligman W, Shaevitz MH, Sharankova R, Shi J, Sinclair J, Smith A, Snider EL, Soderberg M, Söldner-Rembold S, Spentzouris P, Spitz J, Stancari M, John JS, Strauss T, Sutton K, Sword-Fehlberg S, Szelc AM, Tang W, Terao K, Thorpe C, Totani D, Toups M, Tsai YT, Uchida MA, Usher T, Van De Pontseele W, Viren B, Weber M, Wei H, Williams Z, Wolbers S, Wongjirad T, Wospakrik M, Wresilo K, Wright N, Wu W, Yandel E, Yang T, Yarbrough G, Yates LE, Yu HW, Zeller GP, Zennamo J, Zhang C,

Physical review letters.. 2022 April 15128 (15):151801. Epub 1900 01 01.

Aberrant expression of lymphoid enhancer-binding factor 1 in Hodgkin lymphoma.

Ravindran A, Kurtin PJ, King RL, Yuan J, Feldman AL, Rech KL, McPhail ED, Parikh SA, Ding W, Shi M

Human pathology.. 2022 April 12125 :2-10. Epub 04/12/2022.

Up to 8 Years Follow-up From RESONATE-2: First-Line Ibrutinib Treatment for Patients With Chronic Lymphocytic Leukemia.

Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P

Blood advances.. 2022 April 4 Epub 04/04/2022.

Isolated Colonic Post-Transplantation Lymphoproliferative Disease.

Fredrick TW, Ramos GP, Loftus EV

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.. 2022 April 20 (4):e648. Epub 01/29/2021.

Altered expression of NEAT1 variants and P53, PTEN, and BCL-2 genes in patients with acute myeloid leukemia.

Rostami M, Kharajo RS, Parsa-Kondelaji M, Ayatollahi H, Sheikhi M, Keramati MR

Leukemia research.. 2022 April 115 :106807. Epub 02/10/2022.

A Review of Hemophagocytic Lymphohistiocytosis in Patients With HIV.

Tabaja H, Kanj A, El Zein S, Comba IY, Chehab O, Mahmood M

Open forum infectious diseases.. 2022 April 9 (4):ofac071. Epub 02/11/2022.

Evaluation of and Genes Polymorphisms in Iraqi Women with Breast Cancer.

Al-Zubaidy HFS, Majeed SR, Al-Koofee DAF

Archives of Razi Institute.. 2022 April 77 (2):799-808. Epub 04/30/2022.

Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data.

Vanderbilt CM, Bowman AS, Middha S, Petrova-Drus K, Tang YW, Chen X, Wang Y, Chang J, Rekhtman N, Busam KJ, Gupta S, Hameed M, Arcila ME, Ladanyi M, Berger MF, Dogan S, Zehir A

The Journal of molecular diagnostics : JMD.. 2022 March 22 Epub 03/22/2022.

Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Siddiqi T, Coutre S, McKinney M, Barr PM, Rogers K, Mokatrin A, Valentino R, Szoke A, Deshpande S, Zhu A, Arango-Hisijara I, Osei-Bonsu K, Wang M, O'Brien S

Leukemia & lymphoma.. 2022 February 28 :1-9. Epub 02/28/2022.

Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.

Barr PM, Smith S, Roschewski M, O'Brien SM, Sharman JP, Melear JM, Patel P, Calvo R, Yang H, Spurgeon S

Leukemia & lymphoma.. 2022 February 24 :1-5. Epub 02/24/2022.

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.

Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs RW, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson SR, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto JS, Dean JP, Wierda WG, Ghia P

Blood.. 2022 February 23 Epub 02/23/2022.

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact.

Pinney JJ, Blick-Nitko SK, Baran AM, Peterson DR, Whitehead HE, Izumi R, Munugalavadla V, Van DerMeid KR, Barr PM, Zent CS, Elliott MR, Chu CC

Haematologica.. 2022 February 17 Epub 02/17/2022.

Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib.

Wang V, Hanson CA, Tschumper R, Lesnick C, Braggio E, Paietta E, O'Brien SM, Barrientos J, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Erba HP, Stone RM, Litzow MR, Tallman MS, Shanafelt TD, Kay NE

Blood.. 2021 August 18 Epub 08/18/2021.

Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Woyach J, Tedeschi A, Munir T, Siddiqi T, Hillmen P, Byrd JC, Ghia P, Mulligan SP, Dai S, Amaya-Chanaga CI, Dean JP, O'Brien SM, Barr PM

Leukemia & lymphoma.. 2021 August 13 :1-5. Epub 08/13/2021.

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.

Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff A, Davids MS, Baker P, Leslie LA, Rogers KA, Allan JN, Cordoba R, Lopez-Garcia A, Antic D, Pagel JM, Martinez-Calle N, Garcia-Marco JA, Hernández-Rivas JÁ, Miras F, Coombs CC, Österborg A, Seddon AN, López-Jiménez J, Wilson MR, El-Sharkawi D, Wojenski D, Ma S, Munir T, Valenciano S, Seymour E, Barr PM, Pu JJ, Patten PE, Perini GF, Huntington SF, Parry H, Sundaram S, Skarbnik AP, Kamdar M, Jacobs RW, Walter HS, Walewska R, Broom A, Lebowitz S, Isaac K, Portell CA, Ahn IE, Ujjani C, Shadman M, Skånland SS, Chong EA, Mato AR

Blood.. 2021 July 23 Epub 07/23/2021.

Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.

Kumar A, Casulo C, Advani RH, Budde E, Barr PM, Batlevi CL, Caron P, Constine LS, Dandapani SV, Drill E, Drullinsky P, Friedberg JW, Grieve C, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Joseph A, Khan N, Laraque L, Matasar MJ, Moskowitz AJ, Noy A, Palomba ML, Schöder H, Straus DJ, Vemuri S, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2021 April 28 :JCO2100108. Epub 04/28/2021.

Highlights in leukemia and lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary.

Barr PM

Clinical advances in hematology & oncology : H&O.. 2021 March 19 Suppl 11 (3):17-19. Epub 1900 01 01.

Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3K? Inhibitor Therapy.

Mato AR, Ghosh N, Schuster SJ, Lamanna N, Pagel JM, Flinn IW, Barrientos J, Rai KR, Reeves JA, Cheson BD, Barr PM, Kambhampati S, Lansigan F, Pu JJ, Skarbnik AP, Roeker LE, Fonseca G, Sitlinger A, Hamadeh IS, Dorsey C, LaRatta N, Weissbrot H, Luning Prak ET, Tsao PY, Paskalis D, Sportelli P, Miskin HP, Weiss MS, Svoboda J, Brander DM

Blood.. 2020 December 1 Epub 12/01/2020.

Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.

Zent CS, Brady MT, Delage C, Strawderman M, Laniewski N, Contant PN, Kanagaiah P, Sangster MY, Barr PM, Chu CC, Topham DJ, Friedberg JW

Leukemia.. 2020 October 30 Epub 10/30/2020.

Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.

Rodgers TD, Williams AM, Baran A, Reagan PM, Casulo C, Zent CS, Evans A, Friedberg JW, Barr PM

Leukemia & lymphoma.. 2020 October 25 :1-8. Epub 10/25/2020.

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.

Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P,

Cancer medicine. 2020 September 24 Epub 09/24/2020.

Early Progression of Follicular Lymphoma: Biology and Treatment.

Lipof JJ, Barr PM

Hematology/oncology clinics of North America.. 2020 August 34 (4):757-769. Epub 05/05/2020.

Outcomes of COVID-19 in Patients with CLL: A Multicenter, International Experience.

Mato AR, Roeker LE, Lamanna N, Allan J, Leslie LA, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs RW, Ahn IE, Pu JJ, Isaac K, Barr PM, Ujjani C, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hansson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter HS, El-Sharkawi D, Parry H, Wilson MR, Patten PE, Hernández-Rivas JÁ, Miras F, Fernández Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar EB, López-Jiménez J, Naya D, Garcia-Marco JA, Skånland SS, Cordoba R, Eyre TA

Blood.. 2020 July 20 Epub 07/20/2020.

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.

Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2020 July 13 :JCO2000999. Epub 07/13/2020.

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy.

Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Sarraf Yazdy M, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi M, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac KM, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Fox CP, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot HB, Nabhan C, Goodfriend JM, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Allan JN, Eyre TA

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2020 March 20 Epub 03/20/2020.

Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).

Meacham PJ, Williams AM, Strawderman M, Baran AM, Archibald WJ, Wallace DS, Tschernia NP, Burack WR, Barr PM, Zent CS

Leukemia & lymphoma.. 2020 March 16 :1-9. Epub 03/16/2020.

Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment.

Williams AM, van Wijngaarden E, Seplaki CL, Heckler CE, Weber MT, Barr PM, Zent CS, Janelsins MC

Leukemia & lymphoma.. 2020 March 9 :1-9. Epub 03/09/2020.

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.

Eyre TA, Lamanna N, Roeker LE, Ujjani CS, Hill BT, Barr PM, Lansigan E, Cheson BD, Yazdy M, Allan JN, Rhodes J, Schuster SJ, Nabhan C, Skarbnik A, Leslie L, Islam P, Whitaker K, Coombs CC, Tuncer HH, Pagel JM, Jacobs R, Winter AM, Bailey N, Sitlinger A, Schuh AH, Follows G, Fox CP, Brander DM, Shadman M, Mato AR

Haematologica.. 2020 February 20 Epub 02/20/2020.

Initial treatment of B-cell prolymphocytic leukemia with ibrutinib.

Moore J, Baran AM, Meacham PJ, Evans AG, Barr PM, Zent CS

American journal of hematology.. 2020 January 17 Epub 01/17/2020.

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy.

Ujjani C, Mato A, Hill BT, Allan JN, Lansigan F, Jacobs R, Skarbnik A, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M

Blood and lymphatic cancer : targets and therapy.. 2020 10 :1-5. Epub 08/24/2020.

Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma.

Rodgers TD, Baran A, Reagan PM, Casulo C, Zent C, Evans A, Burack R, Williams AM, Friedberg JW, Barr PM

British journal of haematology.. 2019 December 17 Epub 12/17/2019.

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study.

Tam CS, Siddiqi T, Allan JN, Kipps TJ, Flinn IW, Kuss BJ, Opat S, Barr PM, Tedeschi A, Jacobs R, Badoux XC, Ghia P, Sukbuntherng J, Salem AH, Russell K, Eckert K, Zhou C, Ninomoto J, James DF, Wierda WG

Blood.. 2019 November 13134 (Supplement_1):35. Epub 1900 01 01.

The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.

Eyre TA, Roeker LE, Fox CP, Gohill SH, Walewska R, Walter HS, Forconi F, Broom A, Arumainathan A, Brander DM, Allan JN, Schuster SJ, Hill BT, Lansigan F, Cheson BD, Lamanna N, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Pearson L, Pagel JM, Jacobs R, Mato AR

British journal of haematology.. 2019 November 4 Epub 11/04/2019.

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.

Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM

Blood advances.. 2019 October 223 (20):3132-3135. Epub 1900 01 01.

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.

Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ

Leukemia.. 2019 October 18 Epub 10/18/2019.

Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.

Williams AM, Baran AM, Schaffer M, Bushart J, Rich L, Moore J, Barr PM, Zent CS

American journal of hematology.. 2019 October 17 Epub 10/17/2019.

Final analysis from RESONATE: up to 6?years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA

American journal of hematology.. 2019 September 11 Epub 09/11/2019.

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG

Haematologica.. 2019 August 14 Epub 08/14/2019.

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2019 August 9 :JCO1901492. Epub 08/09/2019.

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M

The New England journal of medicine.. 2019 August 1381 (5):432-443. Epub 1900 01 01.

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs.

Matasar MJ, Luminari S, Barr PM, Barta SK, Danilov AV, Hill BT, Phillips TJ, Jerkeman M, Magagnoli M, Nastoupil LJ, Persky DO, Okosun J

The oncologist.. 2019 July 25 Epub 07/25/2019.

.

Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, Leblanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi E, Leonard JP, Kahl B, Smith SM, Friedberg JW

Blood.. 2019 July 22 Epub 07/22/2019.

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2019 July 1525 (14):4264-4270. Epub 04/19/2019.

Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.

Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O'Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M

Clinical lymphoma, myeloma & leukemia.. 2019 July 15 Epub 07/15/2019.

Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation.

Loh KP, Baran A, Lee CY, Alshaibani A, Rutherford SC, Hu J, Casulo C, Barr PM, Friedberg JW, Reagan PM

Leukemia & lymphoma.. 2019 July 8 :1-4. Epub 07/08/2019.

Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.

Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ

British journal of haematology.. 2019 July 186 (2):255-262. Epub 05/01/2019.

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.

Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM

Blood advances.. 2019 June 253 (12):1799-1807. Epub 1900 01 01.

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.

Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP

Blood advances.. 2019 May 283 (10):1568-1573. Epub 1900 01 01.

Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab.

Barr PM

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2019 May 1037 (14):1151-1153. Epub 03/22/2019.

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR

Blood.. 2019 May 9133 (19):2031-2042. Epub 03/06/2019.

Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.

Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC

Haematologica.. 2019 March 28 Epub 03/28/2019.

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis.

O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA

American journal of hematology.. 2019 February 14 Epub 02/14/2019.

Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.

Burger JA, Cramer P, Barr PM, Dilhuydy MS, Mato A, Byrd JC, Chang S, Graef T, Lin T, Tedeschi A

British journal of haematology.. 2019 February 10 Epub 02/10/2019.

Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.

Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS

British journal of haematology.. 2019 February 10 Epub 02/10/2019.

How I treat early relapsing follicular lymphoma.

Casulo C, Barr PM

Blood.. 2019 January 30 Epub 01/30/2019.

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC

The New England journal of medicine.. 2018 December 1 Epub 12/01/2018.

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.

Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L, Zhou L, Verdugo M, Potluri J, Choi M

British journal of haematology.. 2018 November 27 Epub 11/27/2018.

Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.

Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P

American journal of hematology.. 2018 November 93 (11):1402-1410. Epub 10/09/2018.

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.

Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C

American journal of hematology.. 2018 November 93 (11):1394-1401. Epub 09/26/2018.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.

Williams AM, Baran AM, Casulo C, Reagan P, Friedberg JW, Helber M, Moore J, Baloga E, Zent CS, Barr PM

Clinical lymphoma, myeloma & leukemia.. 2018 October 13 Epub 10/13/2018.

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.

O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R

Clinical lymphoma, myeloma & leukemia.. 2018 October 18 (10):648-657.e15. Epub 06/28/2018.

Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.

VanDerMeid KR, Elliott MR, Baran AM, Barr PM, Chu CC, Zent CS

Cancer immunology research.. 2018 October 6 (10):1150-1160. Epub 08/08/2018.

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.

Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P

Haematologica.. 2018 September 103 (9):1502-1510. Epub 06/07/2018.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C

Haematologica.. 2018 September 103 (9):1511-1517. Epub 06/07/2018.

Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.

David RJ, Baran A, Loh KP, Casulo C, Barr PM, Friedberg JW, Reagan PM

Clinical lymphoma, myeloma & leukemia.. 2018 August 29 Epub 08/29/2018.

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.

Phillips T, Barr PM, Park SI, Kolibaba K, Caimi PF, Chhabra S, Kingsley EC, Boyd T, Chen R, Carret AS, Gartner EM, Li H, Yu C, Smith DC

Investigational new drugs.. 2018 August 22 Epub 08/22/2018.

Counterpoint: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?

Barr PM

Oncology.. 2018 August 1532 (8):404, 407-9. Epub 1900 01 01.

A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.

Persky DO, Li H, Rimsza LM, Barr PM, Popplewell LL, Bane CL, Von Gehr A, LeBlanc M, Fisher RI, Smith SM, Friedberg JW

American journal of hematology.. 2018 August 93 (4):486-493. Epub 01/25/2018.

Management of melanoma in patients with chronic lymphocytic leukemia.

Archibald WJ, Meacham PJ, Williams AM, Baran AM, Victor AI, Barr PM, Sahasrahbudhe DM, Zent CS

Leukemia research.. 2018 August 71 :43-46. Epub 07/06/2018.

Phase 1 study of the PI3K? inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.

Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P, Chen X, Barr PM

Blood.. 2018 July 19132 (3):293-306. Epub 04/25/2018.

Survival adjusting for crossover: phase 3 study of ibrutinib . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Coutre S, Tedeschi A, Robak T, Barr PM, Owen C, Bairey O, Burger J, Zhou C, Styles L, James DF, Kipps TJ

Haematologica.. 2018 June 103 (6):e249-e251. Epub 11/23/2017.

Pitfalls of Combining Novel Agents in Lymphoma.

Rodgers TD, Barr PM

Current treatment options in oncology.. 2018 May 2819 (7):35. Epub 05/28/2018.

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaack K, Kennard KH, Timlin C, Landsburg D, Winter A, Nasta SD, Bachow SH, Schuster SJ, Dorsey C, Svoboda J, Barr P, Ujjani CS

Haematologica.. 2018 May 103 (5):874-879. Epub 02/01/2018.

Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.

Williams AM, Baran AM, Meacham PJ, Feldman MM, Valencia HE, Newsom-Stewart C, Gupta N, Janelsins MC, Barr PM, Zent CS

Leukemia & lymphoma.. 2018 March 59 (3):625-632. Epub 07/11/2017.

R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.

Barr PM, Li H, Burack WR, LeBlanc M, Smith SM, Gopal AK, Floyd JD, Persky DO, Press OW, Fisher RI, Friedberg JW

The Lancet. Haematology.. 2018 March 5 (3):e102-e108. Epub 01/26/2018.

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC

Leukemia.. 2018 January 32 (1):83-91. Epub 06/08/2017.

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC

The Lancet. Oncology.. 2018 January 19 (1):65-75. Epub 12/12/2017.

Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies.

Caimi PF, Cooper BW, William BM, Dowlati A, Barr PM, Fu P, Pink J, Xu Y, Lazarus HM, de Lima M, Gerson SL

Oncotarget.. 2017 October 38 (45):79864-79875. Epub 08/09/2017.

Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG).

Dabaja BS, Zelenetz AD, Ng AK, Tsang RW, Qi S, Allen PK, Hodgson D, Ricardi U, Hoppe RT, Advani R, Mauch PM, Constine LS, Specht L, Li Y, Terezakis SA, Wirth A, Reinartz G, Eich HT, Aleman BMP, Barr P, Yahalom J

Annals of oncology : official journal of the European Society for Medical Oncology. 2017 September 128 (9):2185-2190. Epub 1900 01 01.

Treatment of chronic lymphocytic leukemia in older adults.

Rowswell-Turner RB, Barr PM

Journal of geriatric oncology.. 2017 September 8 (5):315-319. Epub 05/06/2017.

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.

Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM

British journal of haematology.. 2017 July 178 (2):286-291. Epub 04/10/2017.

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, Koh B, Ye W, Barr PM, Salles GA, Friedberg JW

Blood.. 2017 June 1129 (22):3037-3039. Epub 03/21/2017.

Long-term safety experience with bendamustine for injection in a real-world setting.

Martin P, Barr PM, James L, Pathak A, Kahl B

Expert opinion on drug safety.. 2017 June 16 (6):647-650. Epub 04/17/2017.

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC

Blood.. 2017 May 11129 (19):2612-2615. Epub 04/03/2017.

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C

Annals of oncology : official journal of the European Society for Medical Oncology. 2017 May 128 (5):1050-1056. Epub 1900 01 01.

Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice.

Jaffe ES, Barr PM, Smith SM

American Society of Clinical Oncology educational book. 2017 May (37):535-546. Epub 1900 01 01.

Efficacy in the margins of NHL with ibrutinib.

Barr PM

Blood.. 2017 April 20129 (16):2207-2208. Epub 1900 01 01.

Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve.

Reagan PM, Barr PM

The Lancet. Haematology.. 2017 April 4 (4):e152-e153. Epub 03/15/2017.

RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.

Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW

British journal of haematology.. 2017 March 176 (5):759-769. Epub 12/19/2016.

Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.

Hunter BD, Herr M, Meacham PJ, Barlaskar F, Evans AG, Burack WR, Liesveld JL, Becker MW, Milner LA, Constine LS, Dhakal S, Barr PM, Friedberg JW, Casulo C

Clinical lymphoma, myeloma & leukemia.. 2017 March 17 (3):145-151. Epub 11/23/2016.

Recommendations for Clinical Trial Development in Follicular Lymphoma.

Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM

Journal of the National Cancer Institute.. 2017 March 109 (3)Epub 12/31/2016.

Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C

Annals of oncology : official journal of the European Society for Medical Oncology. 2017 January 27 Epub 01/27/2017.

Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C

Annals of oncology : official journal of the European Society for Medical Oncology. 2017 January 25 Epub 01/25/2017.

Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice.

Jaffe ES, Barr PM, Smith SM

American Society of Clinical Oncology educational book. 2017 37 :535-546. Epub 1900 01 01.

Deregulation of NF-?B, ie, a useful PMBL marker.

Barr PM

Blood.. 2016 December 8128 (23):2591-2592. Epub 1900 01 01.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM

Blood.. 2016 November 3128 (18):2199-2205. Epub 09/06/2016.

Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.

Reid RM, Baran A, Friedberg JW, Phillips GL, Liesveld JL, Becker MW, Wedow L, Barr PM, Milner LA

Cancer medicine. 2016 November 5 (11):3059-3067. Epub 10/03/2016.

Prognostic Impact of Cell of Origin in Limited-Stage Diffuse Large B-Cell Lymphoma Treated With R-CHOP With or Without Radiation Therapy.

Youn P, Cummings MA, Dhakal S, Burack WR, Casulo C, Barr PM, Friedberg JW, Constine LS

International journal of radiation oncology, biology, physics.. 2016 October 196 (2S):E495. Epub 1900 01 01.

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH

Blood.. 2016 September 15128 (11):1458-64. Epub 07/25/2016.

Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era.

Herr MM, Mohile NA, Barr PM, van Wijngaarden E, Brown EB, Rich DQ

Clinical lymphoma, myeloma & leukemia.. 2016 September 16 (9):e123-e127. Epub 06/08/2016.

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.

Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O

Blood.. 2016 August 25128 (8):1112-20. Epub 07/14/2016.

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.

Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ

Haematologica.. 2016 July 101 (7):e295-8. Epub 05/05/2016.

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 June 1034 (17):2020-7. Epub 04/11/2016.

Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma.

Reagan PM, Baran A, Kelly JL, Barr PM, Casulo C, Chengazi VU, Friedberg JW

Clinical lymphoma, myeloma & leukemia.. 2016 June 16 (6):322-328.e2. Epub 04/02/2016.

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.

Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O'Brien SM, Liem AK, McIntyre RE, Joshi A, Abella-Dominicis E, Hawkins MJ, Reddy A, Di Paolo J, Lee H, He J, Hu J, Dreiling LK, Friedberg JW

Blood.. 2016 May 19127 (20):2411-5. Epub 03/11/2016.

Postibrutinib outcomes in patients with mantle cell lymphoma.

Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA

Blood.. 2016 March 24127 (12):1559-63. Epub 01/13/2016.

Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.

Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW

Leukemia & lymphoma.. 2016 57 (3):635-43. Epub 10/12/2015.

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ,

The New England journal of medicine.. 2015 December 17373 (25):2425-37. Epub 12/06/2015.

Recent advances in the development of Aurora kinases inhibitors in hematological malignancies.

Choudary I, Barr PM, Friedberg J

Therapeutic advances in hematology.. 2015 December 6 (6):282-94. Epub 1900 01 01.

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM

Nature medicine.. 2015 August 21 (8):922-6. Epub 07/20/2015.

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015 July 2033 (21):2399-404. Epub 06/15/2015.

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S

Blood.. 2015 May 7125 (19):2915-22. Epub 03/09/2015.

Rituximab maintenance in follicular lymphoma.

Barr PM

Clinical advances in hematology & oncology : H&O.. 2015 March 13 (3):158-61. Epub 1900 01 01.

Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma.

Hutchinson K, Jahangiri S, Calvi LM, Barr P, Friedberg JW, Kelly JL

Leukemia & lymphoma.. 2015 February 56 (2):508-11. Epub 07/15/2014.

Infection in chronic lymphocytic leukemia: parsimony has its limits.

Barr PM, Zent CS

Leukemia & lymphoma.. 2014 December 55 (12):2683-4. Epub 05/16/2014.

Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.

Jahangiri S, Barr P, Friedberg J

Expert opinion on emerging drugs.. 2014 September 19 (3):367-83. Epub 06/24/2014.

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.

Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM

Blood.. 2014 August 21124 (8):1259-65. Epub 07/11/2014.

Maintenance rituximab should be considered for patients with follicular lymphoma.

Barr PM

Clinical advances in hematology & oncology : H&O.. 2014 August 12 (8):541-3. Epub 1900 01 01.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P,

The New England journal of medicine.. 2014 July 17371 (3):213-23. Epub 05/31/2014.

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.

Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI

Annals of oncology : official journal of the European Society for Medical Oncology. 2014 July 25 (7):1449. Epub 1900 01 01.

Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma".

Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI

Annals of oncology : official journal of the European Society for Medical Oncology. 2014 July 25 (7):1449. Epub 12/04/2019.

Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial.

Brown JR, O'Brien SM, Barrientos JC, Kay NE, Reddy NM, Coutre SE, Tam C, Mulligan SP, Jäger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Fardis M, McGreivy JS, Clow F, James DF, Hillmen P

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014 June 2032 (18_suppl):LBA7008. Epub 1900 01 01.

The ABC of chronic lymphocytic leukemia: etiology of cytopenias is important in staging and management.

Barr PM, Zent CS

Leukemia & lymphoma.. 2014 June 55 (6):1219-20. Epub 11/01/2013.

Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.

Cleary JM, Rodig S, Barr PM, Shinagare AB, Clark JW, Shapiro GI, Armand P

Journal of the National Comprehensive Cancer Network : JNCCN.. 2014 March 112 (3):323-6; quiz 326. Epub 1900 01 01.

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.

Evens AM, Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI

Annals of oncology : official journal of the European Society for Medical Oncology. 2013 December 24 (12):3076-81. Epub 10/20/2013.

Flavopiridol: Judged by the company one keeps.

Barr PM

Leukemia research.. 2013 October 37 (10):1187-8. Epub 07/08/2013.

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia.

Herman SE, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW

Leukemia.. 2013 August 27 (8):1769-73. Epub 02/06/2013.

Fffuse large B-cell lymphoma in the very elderly: the case for refining our clinical trials.

Barr PM

Oncology.. 2013 February 27 (2):140, 142. Epub 1900 01 01.

Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium.

Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore P, Reid EG, Aboulafia DM, Ratner L, Mitsuyasu R, Cooley T, Henry DH, Barr P, Noy A

Leukemia & lymphoma.. 2012 December 53 (12):2383-9. Epub 07/09/2012.

Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies.

Kindwall-Keller TL, Hegerfeldt Y, Meyerson HJ, Margevicius S, Fu P, van Heeckeren W, Lazarus HM, Cooper BW, Gerson SL, Barr P, Tse WW, Curtis C, Fanning LR, Creger RJ, Carlson-Barko JM, Laughlin MJ

Bone marrow transplantation.. 2012 July 47 (7):924-33. Epub 10/17/2011.

Novel agents in mantle cell lymphoma.

Noel MS, Friedberg JW, Barr PM

Best practice & research. Clinical haematology.. 2012 June 25 (2):191-200. Epub 04/30/2012.

Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion.

Barr PM, Wei C, Roger J, Schaefer-Cutillo J, Kelly JL, Rosenberg AF, Jung J, Sanz I, Friedberg JW

Clinical immunology : the official journal of the Clinical Immunology Society.. 2012 March 142 (3):237-42. Epub 01/05/2012.

Non-Hodgkin's Lymphoma in the Elderly

Caimi PF, Barr PM, Berger NA, Lazarus HM.

Drugs & Aging. 2012; 27(3): 211-238.

Novel agents in mantle cell lymphoma

Noel, MS; Friedberg, JW; Barr, PM;.

Best Practices & Resaerch Clinical Haematology. 2012; 25(2): 191-200.

Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.

Carter SJ, Bernstein SH, Friedberg JW, Barr PM

Leukemia research.. 2011 November 35 (11):e223-4. Epub 08/06/2011.

Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.

Lazarus HM, Sommers SR, Arfons LM, Fu P, Ataergin SA, Kaye NM, Liu F, Kindwall-Keller TL, Cooper BW, Laughlin MJ, Creger RJ, Barr PM, Gerson SL, Kaplan D

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2011 July 17 (7):970-8. Epub 04/11/2011.

Getting to the heart of the problem in treating diffuse large B-cell lymphoma.

Barr PM, Friedberg JW

Leukemia & lymphoma.. 2011 July 52 (7):1166-7. Epub 05/25/2011.

Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox.

Dao H, Barr PM, Honda K

Journal of the American Academy of Dermatology.. 2011 June 64 (6):e123-5. Epub 1900 01 01.

Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.

Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, Distelhorst CW

Cell death and differentiation.. 2010 September 17 (9):1381-91. Epub 03/19/2010.

Non-Hodgkin's lymphoma in the elderly.

Caimi PF, Barr PM, Berger NA, Lazarus HM

Drugs & aging.. 2010 March 127 (3):211-38. Epub 1900 01 01.

Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL.

Kaplan D, Meyerson HJ, Li X, Drasny C, Liu F, Costaldi M, Barr P, Lazarus HM

Cytometry. Part B, Clinical cytometry.. 2010 March 78 (2):115-22. Epub 1900 01 01.

Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.

Barr PM, Fu P, Lazarus HM, Horvath N, Gerson SL, Koc ON, Bahlis NJ, Snell MR, Dowlati A, Cooper BW

British journal of haematology.. 2009 October 147 (1):89-96. Epub 06/29/2009.

Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant.

Barr PM, Lazarus HM, Cooper BW, Schluchter MD, Panneerselvam A, Jacobberger JW, Hsu JW, Janakiraman N, Simic A, Dowlati A, Remick SC

American journal of hematology.. 2009 August 84 (8):484-7. Epub 1900 01 01.

Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor.

Rong YP, Barr P, Yee VC, Distelhorst CW

Biochimica et biophysica acta.. 2009 June 1793 (6):971-8. Epub 11/12/2008.

Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation.

Barr PM, Lazarus HM

Current opinion in oncology.. 2008 September 20 (5):502-8. Epub 1900 01 01.

The role of bortezomib in the treatment of lymphoma.

Barr P, Fisher R, Friedberg J

Cancer investigation.. 2007 December 25 (8):766-75. Epub 1900 01 01.

Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.

Barr P, Fu P, Lazarus H, Kane D, Meyerson H, Hartman P, Reyes R, Creger R, Stear K, Laughlin M, Tse W, Cooper B

Leukemia & lymphoma.. 2007 October 48 (10):1940-9. Epub 1900 01 01.

Adenosine depresses transmitter release but is not the basis for 'tetanic fade' at the neuromuscular junction of the rat.

Malinowski MN, Cannady SB, Schmit KV, Barr PM, Schrock JW, Wilson DF

Neuroscience letters.. 1997 July 18230 (2):81-4. Epub 1900 01 01.

The ABC of chronic lymphocytic leukemia: Etiology of cytopenias is important in staging and management

Barr PM, Zent CS.

Leukemia Lymphoma [EPub in press]. .

Books

How I treat early relapsing follicular lymphoma (2019)

Authors: Casulo C, Barr PM

Publisher: Blood 2019

Augmenting Indolent Lymphoma Treatment Options with the Combination of Lenalidomide and Rituximab. (2019)

Authors: Barr PM

Publisher: J Clin Oncology 2019

Pitfalls of Combining Novel Agents in Lymphoma (2018)

Authors: Rodgers TD; Barr PM

Publisher: Current treatment options in oncology 2018

COUNTERPOINT: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma? (2018)

Authors: Barr PM

Publisher: Oncology 2018

Rare B Cell Lymphoproliferative Disorders. In: Textbook of Uncommon Cancers (2017)

Authors: Evans AG, Barr PM

Publisher: Wiley-Blackwell, Oxford, England 2017

Treatment of Chronic Lymphocytic Leukemia in Older Adults (2017)

Authors: Rowswell-Turner R, Barr PM

Publisher: Journal of Geriatric Oncology 2017

Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice (2017)

Authors: Jaffe ES; Barr PM; Smith SM

Publisher: American Society of Clinical Oncology educational book 2017

Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve (2017)

Authors: Reagan PM, Barr PM

Publisher: Lancet Haematol 2017

Efficacy in the margins of NHL with ibrutinib (2017)

Authors: Barr PM

Publisher: Blood 2017

Deregulation of NF-kB, ie, a useful PMBL marker (2016)

Authors: Barr PM

Publisher: Blood 2016

Recent advances in the development of Aurora kinase inhibitors in hematological malignancies (2015)

Authors: Choudary I, Barr PM, Friedberg J.

Publisher: Therapeutic advances in hematology 2015

Rituximab maintenance in follicular lymphoma (2015)

Authors: Barr PM

Publisher: Clinical advances in hematology & oncology 2015

Adult Burkitt Lymphoma and Leukemia. In: Rare Lymphomas (2014)

Authors: Gokbuget N, Barr PM, Friedberg JW, Hsi ED, Ott G

Publisher: Dreyling M, (eds). Springer-Verlag Berlin Heidelberg, New York 2014

Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma (2014)

Authors: Jahangiri S, Friedberg J, Barr PM

Publisher: Expert opinion on emerging drugs 2014

The ABC of CLL: Etiology of Cytopenias is Important in Staging and Management (2014)

Authors: Barr PM, Zent CS

Publisher: Leukemia & Lymphoma 2014

Attempting to avoid chemotherapy in CLL with lenalidomide and rituximab (2014)

Authors: Barr PM

Publisher: doi: 10.1200/JCO.2013.51.5890 2014

Infection in chronic lymphocytic leukemia: parsimony has its limits (2014)

Authors: Barr PM, Zent CS

Publisher: Leukemia & Lymphoma 2014

Maintenance rituximab should be considered for patients with follicular lymphoma. (2014)

Authors: Barr PM

Publisher: Clinical advances in hematology & oncology 2014

Clinical evaluation and management of Burkitt Lymphoma (2013)

Authors: Barr PM, Friedberg JW

Publisher: Clinical Decision Support in Hematology 2013

Neoplastic Diseases of the Blood (2013)

Authors: Barr PM

Publisher: 5th edition. Leukemia Research 2013

Diffuse Large B-Cell Lymphoma in the Very Elderly: The Case for Refining Our Clinical Trials. (2013)

Authors: Barr PM

Publisher: Oncology 2013

Flavopiridol: Judged by the company ones keeps (2013)

Authors: Barr PM

Publisher: Leukemia Research 2013

Textbook of Uncommon Cancers (2012)

Chapter: Rare B Cell Lymphoproliferative Disorders

Authors: Barr PM and Friedberg JW

Publisher: Wiley-Blackwell, Oxford, England 2012

Novel agents in mantle cell lymphoma (2012)

Authors: Noel MS, Friedberg JW, Barr PM

Publisher: Best Practice & Research Clinical Haematology 2012

Rare B Cell Lymphoproliferative Disorders. In: Textbook of Uncommon Cancers (2012)

Authors: Barr PM, Friedberg JW

Publisher: 4th edition. Sekkeres MA, (eds). Wiley-Blackwell, Oxford, England 2012

Getting to the heart of the problem in treating diffuse large B-cell lymphoma (2011)

Authors: Barr PM, Friedberg JW

Publisher: Leuklemia and Lymphoma 2011

Adult Acute Lymphocytic Leukemia: Biology and Treatment (2010)

Chapter: Pharmacology of Acute Lymphoblastic Leukemia Therapy

Authors: Barr PM, Creger RJ, Berger NA

Publisher: Humana Press 2010

Non-Hodgkin's Lymphoma in the Elderly (2010)

Authors: Caimi PF, Barr PM, Berger NA, Lazarus HM

Publisher: Drugs & Aging 2010

Non-Hodgkin Lymphoma. In: Clinical Care Options inPractice (2009)

Authors: Barr PM and Fisher RI

Publisher: Govindan R, Kantarjian H.(eds 2009

Follicular non-Hodgkin lymphoma: long term results of stem cell transplantation (2008)

Authors: Barr PM, Lazarus, HM

Publisher: Current Opinion in Oncology 2008

Non-Hodgkin lymphomas (2008)

Authors: Devita VT, Lawrence TS, Rosenberg SA editors

Publisher: In Cancer, Principles & Practice of Oncology 9th edition 2008

Non-Hodgkin lymphomas (2008)

Authors: Devita VT, Lawrence TS, Rosenberg SA

Publisher: Cancer, Principles & Practice of Oncology 10th edition 2008

Role of Bortezomib in the Treatment of Lymphoma (2007)

Authors: Barr PM, Fisher RI and Friedberg JW.

Publisher: Cancer Investigation 2007

Ratings & Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.